[CLS] O
p O
##k O
- O
p O
##d O
analysis O
of O
h O
##r O
changes O
induced O
by O
s O
- O
carved O
##ilo O
##l O
showed O
a O
greater O
ma O
##ximal O
bra O
##dy O
##card O
##ic O
response O
to O
carved O
##ilo O
##l O
in O
s O
##h O
rats O
( O
e B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
, O
- O
27 O
. O
6 O
± O
3 O
. O
9 O
% O
; O
p O
< O
0 O
. O
05 O
) O
compared O
with O
w O
##ky O
group O
( O
e B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
, O
- O
13 O
. O
4 O
± O
2 O
. O
5 O
% O
) O
. O
[SEP] O
[CLS] O
residues O
were O
re O
##con O
##stituted O
with O
2 O
m O
##l O
of O
65 O
% O
met O
##han O
##ol O
and O
cent O
##ri O
##fu O
##ged O
at O
10 O
, O
000 O
× O
g O
for O
8 O
min O
. O
[SEP] O
[CLS] O
this O
study O
documents O
that O
a O
ta O
##f O
+ O
e O
##v O
##g O
n O
##p O
provides O
sustained O
release O
, O
which O
can O
overcome O
patient O
non O
- O
ad O
##herence O
to O
dos O
##ing O
and O
may O
facilitate O
prediction O
of O
appropriate O
protective O
drug O
concentration O
for O
hi O
##v O
prop O
##hyl O
##ax O
##is O
. O
[SEP] O
[CLS] O
the O
mobile O
phase O
composed O
of O
ace O
##ton O
##it O
##ril O
##e O
- O
0 O
. O
1 O
m O
am O
##mon O
##ium O
ace O
##tate O
( O
15 O
: O
85 O
, O
v O
/ O
v O
) O
was O
delivered O
at O
a O
flow O
rate O
of O
1 O
. O
0 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
in O
a O
second O
phase O
, O
the O
same O
animals O
were O
treated O
with O
the O
alternate O
test O
article O
according O
to O
the O
same O
protocol O
. O
[SEP] O
[CLS] O
the O
bio O
##ad O
##hesion O
of O
each O
component O
in O
the O
m O
##z O
- O
c O
##r O
formulation O
was O
evaluated O
individually O
in O
order O
to O
el O
##uc O
##ida O
##te O
the O
contribution O
of O
each O
component O
to O
bio O
##ad O
##hesion O
. O
[SEP] O
[CLS] O
mean O
) O
and O
young O
subjects O
( O
15 O
. O
7 O
+ O
- O
2 O
. O
1 O
) O
, O
whereas O
total B-PK
clearance I-PK
of O
o O
##xi O
##pur O
##ino O
##l O
was O
significantly O
reduced O
in O
the O
aged O
( O
0 O
. O
24 O
+ O
- O
0 O
. O
03 O
) O
compared O
with O
young O
controls O
( O
0 O
. O
37 O
+ O
- O
0 O
. O
05 O
) O
as O
was O
the O
distribution B-PK
volume I-PK
of O
o O
##xi O
##pur O
##ino O
##l O
( O
0 O
. O
60 O
+ O
- O
0 O
. O
09 O
and O
0 O
. O
84 O
+ O
- O
0 O
. O
07 O
l O
kg O
- O
1 O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
derived O
by O
using O
a O
non O
##com O
##par O
##tment O
##al O
method O
within O
win O
##non O
##lin O
pro O
( O
version O
5 O
. O
2 O
) O
. O
[SEP] O
[CLS] O
the O
initial O
elevation O
in O
il O
- O
10 O
did O
not O
co O
##rrel O
##ate O
with O
clinical O
response O
or O
with O
the O
development O
of O
toxicity O
. O
[SEP] O
[CLS] O
to O
accomplish O
this O
goal O
, O
a O
series O
of O
genetically O
engineered O
derivatives O
of O
ma O
##b O
ch O
##t O
##nt O
- O
3 O
including O
the O
single O
- O
chain O
f O
##v O
, O
di O
##ab O
##ody O
, O
t O
##ria O
##body O
, O
f O
##ab O
, O
and O
f O
( O
a O
##b O
' O
) O
( O
2 O
) O
were O
generated O
and O
expressed O
in O
n O
##s O
##0 O
my O
##elo O
##ma O
cells O
using O
the O
g O
##lut O
##amine O
s O
##ynth O
##eta O
##se O
am O
##p O
##lification O
system O
. O
[SEP] O
[CLS] O
to O
conduct O
a O
phase O
i O
study O
determining O
the O
safety O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
preliminary O
efficacy O
of O
e O
##p O
- O
100 O
, O
a O
novel O
anti O
##can O
##cer O
drug O
consisting O
of O
natural O
l O
##ute O
##ini O
##zing O
- O
hormone O
- O
releasing O
hormone O
( O
l O
##hr O
##h O
) O
l O
##igan O
##d O
linked O
to O
a O
cat O
##ion O
##ic O
membrane O
- O
disrupt O
##ing O
p O
##eptide O
. O
[SEP] O
[CLS] O
the O
in O
##hibition O
effect O
of O
r O
##hein O
on O
tumor O
cell O
growth O
was O
measured O
by O
the O
percentage O
of O
in O
##hibit O
##ed O
cell O
growth O
. O
[SEP] O
[CLS] O
the O
ed B-PK
##50 I-PK
values O
( O
95 O
% O
confidence O
interval O
) O
were O
< O
1 O
. O
0 O
mg O
/ O
kg O
p O
. O
o O
. O
and O
< O
0 O
. O
3 O
mg O
/ O
kg O
s O
. O
c O
. O
for O
anti O
- O
em O
##etic O
activity O
, O
9 O
. O
45 O
( O
4 O
. O
09 O
, O
47 O
. O
79 O
) O
mg O
/ O
kg O
p O
. O
o O
. O
and O
0 O
. O
52 O
( O
0 O
. O
10 O
, O
1 O
. O
08 O
) O
mg O
/ O
kg O
s O
. O
c O
. O
for O
anti O
- O
con O
##st O
##ip O
##ation O
activity O
, O
and O
> O
300 O
mg O
/ O
kg O
p O
. O
o O
. O
and O
> O
30 O
mg O
/ O
kg O
s O
. O
c O
. O
for O
anti O
- O
anal O
##ges O
##ic O
activity O
. O
[SEP] O
[CLS] O
extra O
##he O
##pa O
##tic O
metabolism O
of O
4 O
- O
met O
##hyl O
##um O
##bell O
##ifer O
##one O
and O
lid O
##oc O
##aine O
in O
the O
an O
##he O
##pa O
##tic O
rabbit O
. O
[SEP] O
[CLS] O
the O
challenge O
in O
developing O
oral O
drug O
delivery O
systems O
of O
poorly O
soluble O
basic O
drugs O
is O
primarily O
due O
to O
their O
p O
##h O
dependent O
so O
##lub O
##ility O
. O
[SEP] O
[CLS] O
of O
the O
48 O
and O
24 O
subjects O
who O
met O
all O
entry O
criteria O
and O
were O
enrolled O
in O
the O
sad O
and O
mad O
protocols O
, O
respectively O
, O
all O
completed O
the O
study O
and O
were O
included O
in O
the O
final O
analyses O
. O
[SEP] O
[CLS] O
in O
dissolution O
tests O
, O
all O
cu O
##rc O
##umi O
##n O
formulation O
##s O
exhibited O
marked O
improvement O
in O
the O
dissolution O
behavior O
when O
compared O
with O
crystal O
##line O
cu O
##rc O
##umi O
##n O
. O
[SEP] O
[CLS] O
the O
parameter O
estimates O
and O
model O
fit O
for O
models O
with O
body O
weight O
effect O
estimated O
or O
fixed O
to O
zero O
were O
very O
similar O
. O
[SEP] O
[CLS] O
to O
obtain O
tissue O
and O
plasma O
samples O
, O
five O
pigs O
which O
received O
the O
in O
##tra O
##mus O
##cular O
injection O
were O
randomly O
killed O
at O
2 O
, O
6 O
, O
10 O
, O
24 O
, O
48 O
, O
72 O
, O
and O
96 O
h O
, O
respectively O
, O
whereas O
those O
in O
control O
group O
were O
sacrificed O
at O
96 O
h O
. O
samples O
of O
plasma O
and O
tissues O
, O
including O
muscle O
, O
lung O
, O
heart O
, O
kidney O
, O
liver O
, O
and O
muscle O
at O
the O
injection O
site O
, O
were O
collected O
from O
each O
animal O
. O
[SEP] O
[CLS] O
inspection O
of O
the O
raw O
data O
showed O
that O
148 O
of O
the O
163 O
error O
codes O
were O
not O
applicable O
to O
the O
four O
primary O
rot O
##em O
parameters O
evaluated O
in O
this O
study O
. O
[SEP] O
[CLS] O
at O
48 O
h O
post O
- O
administration O
, O
p O
##t O
##x O
was O
still O
detected O
in O
the O
tumor O
in O
the O
dual O
- O
n O
##ps O
group O
, O
however O
, O
p O
##t O
##x O
levels O
were O
below O
the O
limit O
of O
detection O
in O
the O
tumor O
in O
the O
free O
p O
##t O
##x O
+ O
ever O
group O
. O
[SEP] O
[CLS] O
eight O
adult O
volunteers O
with O
severe O
stable O
c O
##ri O
( O
mean O
c O
##rea O
##tin O
##ine O
clearance O
, O
0 O
. O
28 O
m O
##l O
/ O
s O
; O
range O
, O
0 O
. O
15 O
to O
0 O
. O
47 O
m O
##l O
/ O
s O
) O
were O
recruited O
from O
the O
out O
##patient O
ne O
##ph O
##rol O
##ogy O
clinics O
of O
in O
##dian O
##a O
university O
medical O
center O
. O
[SEP] O
[CLS] O
f O
##gt O
##1 O
behave O
##s O
like O
natural O
functional O
fi O
##bri O
##no O
##gen O
, O
and O
its O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
are O
in O
line O
with O
those O
expected O
from O
a O
fi O
##bri O
##no O
##gen O
concentrate O
. O
[SEP] O
[CLS] O
overall O
, O
most O
compounds O
reached O
their O
maximum B-PK
concentrations I-PK
within O
2 O
h O
, O
whereas O
slow O
absorption O
was O
observed O
for O
the O
four O
di O
##ter O
##pen O
##e O
##quin O
##oned O
##eri O
##vat O
##ives O
( O
t B-PK
##max I-PK
, O
8 O
h O
) O
. O
[SEP] O
[CLS] O
as O
previously O
shown O
for O
im O
##ati O
##ni O
##b O
, O
therapeutic O
drug O
monitoring O
( O
t O
##d O
##m O
) O
of O
ve O
##mura O
##fen O
##ib O
should O
be O
important O
to O
measure O
efficacy O
of O
the O
treatment O
in O
me O
##lan O
##oma O
patient O
. O
[SEP] O
[CLS] O
animal O
bio O
##dis O
##tribution O
data O
and O
serial O
micro O
##pet O
images O
demonstrated O
rapid O
tumor O
up O
##take O
and O
rapid O
clearance B-PK
from O
the O
blood O
and O
all O
tissues O
except O
kidney O
. O
[SEP] O
[CLS] O
treatment O
of O
ex O
##uda O
##tive O
age O
- O
related O
mac O
##ular O
de O
##gene O
##ration O
with O
a O
designed O
an O
##ky O
##rin O
repeat O
protein O
that O
binds O
vascular O
end O
##oth O
##eli O
##al O
growth O
factor O
: O
a O
phase O
i O
/ O
ii O
study O
. O
[SEP] O
[CLS] O
experiments O
in O
a O
co O
##lla O
##gen O
- O
induced O
art O
##hr O
##itis O
mouse O
model O
demonstrated O
that O
the O
magnitude O
##s O
of O
therapeutic O
effects O
, O
as O
judged O
by O
clinical O
scores O
and O
his O
##tology O
, O
were O
significantly O
enhanced O
by O
the O
sustained O
delivery O
of O
p O
##eg O
- O
trail O
, O
with O
the O
order O
of O
na O
##no O
##com O
##plex O
in O
1 O
% O
ha O
> O
na O
##no O
##com O
##plex O
in O
p O
##bs O
> O
p O
##eg O
- O
trail O
in O
p O
##bs O
. O
[SEP] O
[CLS] O
a O
##es O
were O
coded O
by O
using O
the O
medical O
dictionary O
for O
drug O
regulatory O
activities O
( O
me O
##dd O
##ra O
; O
v O
12 O
. O
0 O
) O
. O
[SEP] O
[CLS] O
the O
predict O
##ive O
performance O
of O
the O
final O
model O
was O
evaluated O
with O
a O
population O
prediction O
- O
corrected O
visual O
predict O
##ive O
check O
( O
p O
##c O
##v O
##p O
##c O
) O
through O
1000 O
simulation O
##s O
of O
the O
data O
##set O
[ O
24 O
] O
. O
[SEP] O
[CLS] O
the O
c O
##s O
##f O
penetration O
of O
p O
##ex O
##ida O
##rt O
##ini O
##b O
after O
single O
- O
dose O
oral O
administration O
to O
n O
##hp O
##s O
was O
limited O
. O
[SEP] O
[CLS] O
c O
##t O
##x O
and O
the O
internal O
standard O
( O
w O
##ogo O
##nin O
) O
were O
detected O
using O
a O
tandem O
mass O
s O
##pect O
##rome O
##ter O
in O
positive O
multiple O
reaction O
monitoring O
mode O
. O
[SEP] O
[CLS] O
there O
was O
also O
a O
rapid O
de O
##ple O
##tion O
in O
c O
##d O
##19 O
+ O
b O
- O
cells O
after O
the O
first O
o O
##bin O
##ut O
##uz O
##uma O
##b O
in O
##fusion O
( O
i O
. O
e O
. O
b O
- O
cell O
de O
##ple O
##tion O
; O
supplement O
##ary O
data O
, O
fi O
##g O
. O
4 O
) O
. O
[SEP] O
[CLS] O
ve O
##nous O
blood O
was O
collected O
by O
ve O
##ni O
##pu O
##nc O
##ture O
at O
t O
##0 O
in O
a O
non O
- O
fast O
##ing O
state O
to O
measure O
the O
o O
##me O
##ga O
- O
3 O
index O
, O
and O
at O
t O
##1 O
and O
t O
##8 O
after O
an O
overnight O
fast O
to O
measure O
pre O
##de O
##fine O
##d O
bio O
##chemical O
parameters O
as O
shown O
in O
table O
2 O
. O
[SEP] O
[CLS] O
the O
ass O
##ays O
were O
valid O
##ated O
over O
the O
concentration O
range O
of O
3 O
. O
5 O
- O
143 O
##36 O
. O
0 O
ng O
x O
m O
##l O
( O
- O
1 O
) O
in O
human O
plasma O
. O
[SEP] O
[CLS] O
the O
protocol O
was O
approved O
by O
the O
institutional O
review O
board O
of O
kn O
##uh O
. O
[SEP] O
[CLS] O
to O
assess O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
p O
##har O
##ma O
##co O
##dynamic O
dose O
- O
responses O
of O
continuous O
in O
##fusion O
regime O
##ns O
of O
la O
##nso O
##pra O
##zo O
##le O
. O
[SEP] O
[CLS] O
a O
good O
correlation O
of O
drug O
absorption O
in O
v O
##ivo O
and O
drug O
release O
in O
v O
##it O
##ro O
( O
r O
( O
2 O
) O
= O
0 O
. O
978 O
##5 O
) O
was O
observed O
. O
[SEP] O
[CLS] O
the O
subjects O
were O
assessed O
throughout O
the O
study O
to O
determine O
if O
they O
were O
experiencing O
adverse O
events O
. O
[SEP] O
[CLS] O
almost O
all O
of O
the O
g O
##ra O
##vid O
##ae O
described O
the O
o O
##bs O
##te O
##tric O
anal O
##ges O
##ia O
as O
good O
or O
adequate O
. O
[SEP] O
[CLS] O
residual O
g O
##z O
- O
de O
levels O
in O
di O
##st O
##ille O
##d O
water O
were O
79 O
. O
3 O
% O
± O
3 O
. O
0 O
% O
at O
10 O
hours O
( O
figure O
4 O
##a O
) O
and O
83 O
. O
7 O
% O
± O
9 O
. O
8 O
% O
by O
one O
day O
( O
figure O
4 O
##c O
) O
after O
in O
##cu O
##bation O
at O
37 O
##° O
##c O
. O
[SEP] O
[CLS] O
the O
m O
##t O
##d O
for O
schedule O
4 O
/ O
2 O
and O
the O
c O
##dd O
schedule O
was O
sun O
##iti O
##ni O
##b O
37 O
. O
5 O
mg O
/ O
d O
plus O
cape O
##ci O
##ta O
##bine O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
twice O
per O
day O
; O
the O
m O
##t O
##d O
for O
schedule O
2 O
/ O
1 O
was O
sun O
##iti O
##ni O
##b O
50 O
mg O
/ O
d O
plus O
cape O
##ci O
##ta O
##bine O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
twice O
per O
day O
. O
[SEP] O
[CLS] O
effects O
of O
and O
##ros O
##tero O
##ne O
on O
the O
protective O
action O
of O
various O
anti O
##ep O
##ile O
##ptic O
drugs O
against O
ma O
##ximal O
electro O
##sh O
##ock O
- O
induced O
seizure O
##s O
in O
mice O
. O
[SEP] O
[CLS] O
the O
average O
number O
of O
nod O
##aga O
molecules O
per O
protein O
was O
q O
##uant O
##ified O
by O
is O
##oto O
##pic O
di O
##lution O
as O
previously O
described O
[ O
19 O
] O
and O
was O
1 O
. O
4 O
. O
[SEP] O
[CLS] O
at O
180 O
mg O
/ O
m O
##2 O
, O
cm B-PK
##ax I-PK
was O
2 O
. O
9 O
+ O
- O
1 O
. O
2 O
micro O
##g O
/ O
m O
##l O
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
78 O
. O
7 O
+ O
- O
24 O
. O
4 O
h O
, O
c B-PK
##lt I-PK
##ot I-PK
25 O
. O
3 O
+ O
- O
4 O
. O
6 O
m O
##l O
/ O
min O
and O
au B-PK
##c I-PK
203 O
+ O
- O
71 O
. O
5 O
h O
x O
micro O
##g O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
a O
q O
##uad O
##ratic O
re O
##gression O
( O
weighted O
1 O
/ O
concentration O
) O
was O
used O
to O
fit O
ca O
##li O
##bra O
##tion O
curves O
over O
the O
concentration O
range O
1 O
. O
01 O
- O
220 O
##0 O
ng O
/ O
m O
##l O
with O
an O
equation O
y O
= O
a O
##x O
##2 O
+ O
b O
##x O
+ O
c O
for O
free O
payload O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
obtained O
after O
single O
in O
##tra O
##per O
##ito O
##nea O
##l O
injection O
##s O
were O
calculated O
according O
to O
a O
two O
- O
compartment O
model O
using O
j O
##mp O
7 O
. O
0 O
. O
1 O
( O
sa O
##s O
institute O
in O
##c O
. O
) O
software O
for O
approximation O
fit O
of O
the O
concentration O
curves O
. O
[SEP] O
[CLS] O
reproductive O
toxicity O
studies O
, O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
, O
single O
- O
and O
repeat O
- O
dose O
in O
##tra O
##per O
##ito O
##nea O
##l O
or O
in O
##tra O
##ven O
##ous O
toxicity O
studies O
in O
mice O
, O
rats O
and O
monkeys O
were O
conducted O
to O
assess O
the O
toxicity O
of O
l O
##hr O
##h O
- O
p O
##e O
##40 O
. O
[SEP] O
[CLS] O
after O
trans O
##fusion O
with O
flu O
##oso O
##l O
da O
20 O
% O
or O
s O
##trom O
##a O
- O
free O
hem O
##og O
##lo O
##bin O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
anti O
##py O
##rine O
, O
di O
##az O
##ep O
##am O
, O
and O
pen O
##ici O
##llin O
were O
unchanged O
when O
compared O
to O
control O
animals O
. O
[SEP] O
[CLS] O
the O
p O
##t O
##c O
##l O
sub O
##type O
was O
diagnosed O
in O
each O
institution O
from O
les O
##ion O
bio O
##psy O
specimens O
and O
confirmed O
by O
an O
independent O
path O
##ology O
review O
committee O
. O
[SEP] O
[CLS] O
human O
est O
##rogen O
receptor O
‐ O
α O
( O
er O
##α O
) O
and O
est O
##rogen O
receptor O
‐ O
β O
( O
er O
##β O
) O
expressed O
in O
s O
##f O
##9 O
insect O
cells O
were O
prepared O
individually O
in O
modified O
t O
##ris O
– O
h O
##c O
##l O
buffer O
p O
##h O
7 O
. O
4 O
. O
[SEP] O
[CLS] O
these O
include O
nearly O
complete O
enter O
##al O
absorption O
and O
virtual O
absence O
of O
liver O
first O
- O
pass O
metabolism O
, O
both O
resulting O
in O
high O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
long O
plasma B-PK
half I-PK
- I-PK
life I-PK
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
that O
are O
linear O
over O
a O
wide O
dose O
range O
and O
independent O
of O
age O
, O
food O
intake O
and O
h O
##ydro O
##xy O
##lator O
status O
, O
low O
plasma O
protein O
binding O
, O
and O
a O
1 O
: O
1 O
ratio O
of O
he O
##pa O
##tic O
meta O
##bol O
##ization O
to O
re O
##nal O
elimination O
of O
the O
un O
##altered O
substance O
. O
[SEP] O
[CLS] O
seventy O
subjects O
were O
randomly O
assigned O
to O
8 O
in O
##cre O
##mental O
dos O
##age O
groups O
( O
2 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
100 O
, O
200 O
and O
400 O
µ O
##g O
) O
. O
[SEP] O
[CLS] O
peak B-PK
plasma I-PK
levels I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
##h I-PK
showed O
no O
clear O
increase O
after O
repeated O
dos O
##ing O
, O
but O
mean O
t B-PK
##rough I-PK
plasma I-PK
levels I-PK
increased O
with O
increasing O
numbers O
of O
injection O
##s O
up O
to O
at O
least O
the O
first O
20 O
weeks O
of O
treatment O
, O
indicating O
continued O
tissue O
exposure O
at O
once O
- O
weekly O
dos O
##ing O
intervals O
. O
[SEP] O
[CLS] O
the O
f O
##e O
- O
b O
##lf O
or O
tax O
##ol O
- O
loaded O
n O
##cs O
indicated O
as O
a O
##ec O
- O
c O
##p O
- O
f O
##e O
- O
b O
##lf O
or O
a O
##ec O
- O
c O
##p O
- O
tax O
##ol O
n O
##cs O
, O
respectively O
, O
were O
made O
by O
combination O
of O
ion O
##ic O
gel O
##ation O
and O
na O
##no O
##p O
##re O
##ci O
##pit O
##ation O
. O
[SEP] O
[CLS] O
the O
radio O
##chemical O
purity O
of O
the O
compound O
was O
determined O
to O
be O
higher O
##than O
95 O
% O
. O
[SEP] O
[CLS] O
patients O
were O
randomly O
assigned O
to O
once O
- O
daily O
l O
##y O
##21 O
##9 O
##60 O
##44 O
( O
final O
doses O
of O
125 O
or O
250 O
mg O
/ O
d O
) O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
the O
parameters O
of O
the O
final O
model O
are O
presented O
in O
table O
3 O
. O
[SEP] O
[CLS] O
to O
test O
whether O
13 O
##cis O
##ra O
results O
in O
a O
decrease O
in O
c O
##y O
##p O
##2 O
##d O
##6 O
activity O
in O
the O
clinic O
, O
a O
d O
##di O
study O
was O
conducted O
using O
de O
##x O
##trom O
##eth O
##or O
##pha O
##n O
as O
a O
probe O
. O
[SEP] O
[CLS] O
the O
en O
##cap O
##sul O
##ated O
c O
##f O
in O
the O
three O
batch O
##es O
was O
measured O
after O
pu O
##rification O
of O
the O
lip O
##oso O
##mes O
. O
[SEP] O
[CLS] O
the O
per O
- O
oral O
administration O
of O
[ O
3 O
##h O
] O
di O
##os O
##gen O
##in O
yielded O
12 O
% O
of O
the O
given O
dose O
distributed O
throughout O
: O
liver O
, O
s O
##ple O
##en O
, O
e O
##pid O
##idy O
##mal O
fat O
, O
brain O
and O
car O
##cas O
##s O
of O
the O
rat O
. O
[SEP] O
[CLS] O
the O
disposition O
of O
[ O
14 O
##c O
] O
sa O
##lm O
##eter O
##ol O
x O
##ina O
##fo O
##ate O
, O
a O
new O
inhaled O
beta O
2 O
- O
ad O
##ren O
##oc O
##ept O
##or O
ago O
##nist O
with O
both O
br O
##on O
##cho O
##di O
##lator O
and O
anti O
##in O
##f O
##lam O
##mat O
##ory O
activity O
, O
has O
been O
studied O
in O
laboratory O
animals O
and O
humans O
following O
in O
##tra O
##ven O
##ous O
and O
oral O
administration O
. O
[SEP] O
[CLS] O
phase O
i O
study O
of O
s O
- O
1 O
and O
bi O
##week O
##ly O
do O
##ce O
##ta O
##xe O
##l O
combination O
ch O
##em O
##otherapy O
for O
advanced O
and O
re O
##current O
gas O
##tric O
cancer O
. O
[SEP] O
[CLS] O
1 O
##h O
nm O
##r O
( O
500 O
m O
##h O
##z O
, O
d O
##ms O
##o O
- O
d O
##6 O
) O
: O
δ O
10 O
. O
37 O
( O
s O
, O
1 O
##h O
, O
n O
##h O
) O
, O
8 O
. O
94 O
( O
d O
, O
j O
= O
4 O
. O
0 O
h O
##z O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
8 O
. O
52 O
( O
s O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
8 O
. O
34 O
( O
d O
, O
j O
= O
15 O
. O
5 O
h O
##z O
, O
1 O
##h O
, O
al O
##ken O
##e O
hydrogen O
) O
, O
8 O
. O
33 O
( O
br O
##s O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
8 O
. O
16 O
( O
d O
, O
j O
= O
8 O
. O
5 O
h O
##z O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
8 O
. O
08 O
( O
m O
, O
2 O
##h O
, O
a O
##r O
- O
h O
) O
, O
7 O
. O
91 O
( O
d O
, O
j O
= O
4 O
. O
0 O
h O
##z O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
7 O
. O
83 O
( O
m O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
7 O
. O
60 O
( O
m O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
7 O
. O
28 O
( O
d O
, O
j O
= O
15 O
. O
5 O
h O
##z O
, O
1 O
##h O
, O
al O
##ken O
##e O
hydrogen O
) O
, O
7 O
. O
27 O
( O
m O
, O
1 O
##h O
, O
a O
##r O
- O
h O
) O
, O
3 O
. O
79 O
– O
3 O
. O
63 O
( O
m O
, O
5 O
##h O
, O
o O
##ch O
##3 O
+ O
ch O
##2 O
) O
, O
3 O
. O
48 O
( O
t O
, O
j O
= O
6 O
. O
5 O
h O
##z O
, O
2 O
##h O
, O
ch O
##2 O
) O
, O
1 O
. O
94 O
( O
m O
, O
2 O
##h O
, O
ch O
##2 O
) O
, O
1 O
. O
89 O
– O
1 O
. O
81 O
( O
m O
, O
2 O
##h O
, O
ch O
##2 O
) O
. O
[SEP] O
[CLS] O
for O
plasma O
levels O
of O
s O
##met O
, O
s O
##ve O
##g O
##f O
##r O
##2 O
, O
ve O
##g O
##fa O
and O
h O
##g O
##f O
, O
marker O
base O
##line O
and O
changes O
from O
base O
##line O
were O
analyzed O
at O
each O
time O
point O
using O
analysis O
of O
variance O
, O
and O
their O
relationships O
with O
plasma O
fore O
##tin O
##ib O
concentrations O
and O
clinical O
outcome O
( O
sum O
of O
longest O
diameter O
[ O
s O
##ld O
] O
, O
p O
##fs O
and O
re O
##cist O
response O
) O
were O
examined O
using O
spear O
##man O
analysis O
. O
[SEP] O
[CLS] O
capsule O
##s O
were O
taken O
with O
240 O
m O
##l O
of O
water O
while O
subjects O
were O
fast O
##ed O
. O
[SEP] O
[CLS] O
the O
trial O
is O
conducted O
in O
accordance O
with O
the O
ethical O
principles O
laid O
down O
in O
the O
declaration O
of O
he O
##ls O
##ink O
##i O
( O
as O
revised O
in O
1983 O
) O
, O
the O
guide O
##line O
for O
good O
clinical O
practice O
( O
chin O
##a O
, O
2003 O
and O
exposure O
draft O
in O
2017 O
) O
, O
and O
local O
laws O
. O
[SEP] O
[CLS] O
protein O
binding O
of O
ma O
##rb O
##of O
##lo O
##xa O
##cin O
was O
not O
significantly O
different O
in O
healthy O
and O
disease O
##d O
ca O
##lves O
. O
[SEP] O
[CLS] O
parasite O
slope O
half B-PK
- I-PK
life I-PK
for O
each O
patient O
was O
calculated O
from O
log O
##e O
( O
2 O
) O
/ O
k O
= O
0 O
. O
69 O
##3 O
, O
where O
k B-PK
is O
the O
clearance B-PK
rate I-PK
constant I-PK
[ O
15 O
] O
. O
[SEP] O
[CLS] O
this O
consent O
extended O
to O
the O
use O
of O
biological O
, O
his O
##top O
##ath O
##ological O
, O
radio O
##logical O
, O
bio O
##chemical O
, O
and O
clinical O
data O
for O
scientific O
purposes O
. O
[SEP] O
[CLS] O
the O
total B-PK
clearance I-PK
, I-PK
c I-PK
##lt I-PK
##ot I-PK
; O
he B-PK
##pa I-PK
##tic I-PK
extraction I-PK
ratio I-PK
, I-PK
eh I-PK
; O
and O
liver B-PK
- I-PK
to I-PK
- I-PK
plasma I-PK
concentration I-PK
ratio I-PK
, I-PK
k I-PK
##p I-PK
values O
, O
decreased O
as O
the O
in O
##fusion O
rate O
increased O
. O
[SEP] O
[CLS] O
following O
su O
##gam O
##made O
##x O
16 O
mg O
/ O
kg O
in O
##fusion O
, O
peak B-PK
su I-PK
##gam I-PK
##made I-PK
##x I-PK
concentration I-PK
was O
197 O
μ O
##g O
/ O
m O
##l O
, O
clearance B-PK
was O
99 O
. O
7 O
m O
##l O
/ O
min O
, O
and O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
at I-PK
equilibrium I-PK
was O
10 O
. O
5 O
l O
. O
plasma O
su O
##gam O
##made O
##x O
concentrations O
showed O
a O
p O
##oly O
##ex O
##po O
##nent O
##ial O
decline O
over O
time O
, O
with O
an O
overall O
geometric O
mean O
( O
c O
##v O
% O
) O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
145 O
minutes O
( O
17 O
. O
9 O
% O
) O
( O
139 O
minutes O
( O
17 O
. O
7 O
% O
) O
for O
males O
; O
152 O
minutes O
( O
18 O
. O
6 O
% O
) O
for O
females O
) O
. O
[SEP] O
[CLS] O
the O
car O
##box O
##yl O
and O
amino O
functional O
m O
##oi O
##eti O
##es O
present O
on O
the O
link O
##er O
portions O
of O
p O
##da O
and O
p O
##d O
##b O
, O
respectively O
, O
may O
facilitate O
their O
con O
##ju O
##gation O
to O
na O
##no O
##par O
##tic O
##les O
to O
tail O
##or O
m O
##or O
##phine O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
specific O
targeting O
. O
[SEP] O
[CLS] O
reduced O
- O
intensity O
transplant O
##s O
can O
also O
achieve O
cure O
and O
result O
in O
less O
treatment O
- O
related O
mortality O
but O
higher O
re O
##lap O
##se O
rates O
. O
[SEP] O
[CLS] O
aggressive O
amino O
##gly O
##cos O
##ide O
dos O
##ing O
immediately O
followed O
by O
individual O
##ized O
p O
##har O
##ma O
##co O
##kin O
##etic O
monitoring O
would O
ensure O
that O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
targets O
are O
achieved O
early O
in O
therapy O
. O
[SEP] O
[CLS] O
the O
error O
in O
fitted O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
k B-PK
( I-PK
trans I-PK
) I-PK
and O
v B-PK
( I-PK
e I-PK
) I-PK
, O
was O
calculated O
. O
[SEP] O
[CLS] O
this O
was O
an O
open O
- O
label O
, O
random O
##ized O
, O
single O
- O
dose O
, O
two O
- O
way O
crossover O
study O
in O
healthy O
male O
subjects O
. O
[SEP] O
[CLS] O
the O
most O
frequent O
drug O
- O
related O
non O
##hem O
##ato O
##log O
##ic O
toxic O
##ities O
included O
di O
##ar O
##r O
##hea O
( O
16 O
patients O
) O
, O
nausea O
( O
8 O
patients O
) O
, O
and O
al O
##ope O
##cia O
( O
7 O
patients O
) O
. O
[SEP] O
[CLS] O
ve O
##nous O
blood O
samples O
were O
taken O
before O
cocaine O
application O
and O
15 O
, O
30 O
, O
45 O
, O
60 O
, O
90 O
, O
120 O
, O
150 O
, O
180 O
, O
240 O
min O
later O
. O
[SEP] O
[CLS] O
the O
study O
employed O
an O
open O
- O
label O
, O
two O
- O
co O
##hor O
##t O
, O
parallel O
design O
. O
[SEP] O
[CLS] O
further O
##more O
, O
based O
on O
predictions O
from O
the O
b O
##l O
##rm O
, O
the O
m O
##t O
##d O
was O
more O
than O
700 O
mg O
once O
daily O
, O
with O
a O
low O
probability O
of O
over O
##dos O
##e O
at O
the O
600 O
mg O
once O
- O
daily O
dose O
. O
[SEP] O
[CLS] O
data O
were O
split O
into O
an O
index O
and O
a O
valid O
##ation O
data O
set O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
of O
anti O
##mal O
##aria O
##l O
drugs O
are O
often O
affected O
by O
pregnancy O
, O
resulting O
in O
lower O
drug O
concentrations O
and O
a O
consequently O
higher O
risk O
of O
treatment O
failure O
. O
[SEP] O
[CLS] O
when O
these O
samples O
were O
re O
- O
analyzed O
, O
the O
average O
total O
serum O
f O
##olate O
was O
21 O
. O
3 O
nm O
( O
s O
. O
d O
. O
± O
5 O
. O
2 O
) O
by O
the O
micro O
##bio O
##logical O
ass O
##ay O
, O
and O
serum O
5 O
- O
m O
##th O
##f O
was O
18 O
. O
1 O
nm O
( O
s O
. O
d O
. O
± O
4 O
. O
2 O
) O
by O
hp O
##l O
##c O
( O
85 O
% O
of O
total O
f O
##olate O
) O
. O
[SEP] O
[CLS] O
it O
was O
found O
that O
micro O
##em O
##ul O
##sions O
with O
x O
##1 O
and O
x O
##3 O
at O
low O
levels O
and O
x O
##2 O
at O
high O
levels O
had O
a O
shortened O
la B-PK
##g I-PK
time I-PK
. O
[SEP] O
[CLS] O
thus O
, O
30 O
patients O
( O
66 O
. O
7 O
% O
female O
) O
underwent O
analysis O
after O
receiving O
p O
##y O
##c O
##no O
##gen O
##ol O
##® O
( O
“ O
p O
+ O
” O
; O
9 O
females O
, O
6 O
males O
) O
or O
no O
treatment O
as O
the O
control O
group O
( O
“ O
co O
” O
; O
11 O
females O
, O
4 O
males O
) O
. O
[SEP] O
[CLS] O
the O
far O
- O
reaching O
effects O
that O
result O
from O
pace O
##4 O
in O
##hibition O
are O
consistent O
with O
the O
role O
of O
pace O
##4 O
as O
a O
hub O
protein O
for O
the O
activation O
of O
cancer O
promoting O
factors O
in O
pro O
##state O
cancer O
. O
[SEP] O
[CLS] O
four O
other O
groups O
of O
animals O
received O
the O
same O
pre O
##tre O
##at O
##ment O
and O
non O
- O
labeled O
do O
##x O
##or O
##ubi O
##cin O
. O
[SEP] O
[CLS] O
the O
geometric O
mean O
ratios O
( O
90 O
% O
confidence O
interval O
) O
of O
g O
##p O
##20 O
##15 O
/ O
et O
##n O
for O
cm B-PK
##ax I-PK
( O
1 O
. O
11 O
[ O
1 O
. O
05 O
– O
1 O
. O
17 O
] O
) O
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
##last I-PK
( O
0 O
. O
98 O
[ O
0 O
. O
94 O
– O
1 O
. O
02 O
] O
) O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
( O
0 O
. O
96 O
[ O
0 O
. O
93 O
– O
1 O
. O
00 O
] O
) O
were O
within O
the O
pre O
##de O
##fine O
##d O
bio O
##e O
##qui O
##valence O
range O
of O
0 O
. O
80 O
– O
1 O
. O
25 O
. O
[SEP] O
[CLS] O
according O
to O
the O
who O
report O
in O
2016 O
, O
there O
was O
a O
growing O
number O
of O
tram O
##ado O
##l O
abuse O
##rs O
alone O
or O
in O
combination O
with O
ps O
##ych O
##oa O
##ctive O
substances O
such O
as O
m O
##d O
##ma O
in O
particular O
in O
some O
middle O
east O
countries O
. O
[SEP] O
[CLS] O
the O
limited O
data O
suggest O
that O
the O
volume B-PK
of I-PK
distribution I-PK
of O
do O
##but O
##amine O
was O
related O
to O
the O
extent O
of O
ed O
##ema O
. O
[SEP] O
[CLS] O
we O
previously O
reported O
a O
phase O
i O
study O
of O
the O
safety O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
sat O
##rap O
##lat O
##in O
in O
patients O
with O
re O
##fra O
##ctor O
##y O
solid O
tumors O
and O
varying O
degrees O
of O
re O
##nal O
imp O
##air O
##ment O
. O
[SEP] O
[CLS] O
the O
u O
##v O
detection O
wavelength O
was O
248 O
nm O
, O
and O
the O
sample O
injection O
volume O
was O
8 O
μ O
##l O
. O
[SEP] O
[CLS] O
healthy O
men O
and O
women O
( O
of O
non O
- O
child O
- O
bearing O
potential O
or O
those O
using O
an O
acceptable O
con O
##tra O
##ceptive O
) O
aged O
≥ O
##18 O
years O
and O
weighing O
50 O
– O
100 O
kg O
( O
110 O
– O
220 O
lbs O
) O
were O
recruited O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
oral O
i O
##va O
##bra O
##dine O
in O
healthy O
cats O
. O
[SEP] O
[CLS] O
the O
f B-PK
, O
d O
, O
and O
v B-PK
##d I-PK
represent O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
dose O
, O
and O
volume B-PK
of I-PK
distribution I-PK
, O
respectively O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
and O
p O
##har O
##ma O
##co O
##dynamic O
( O
p O
##d O
) O
models O
were O
developed O
to O
assess O
dose O
selection O
, O
identify O
significant O
a O
##ed O
drug O
interactions O
, O
and O
q O
##uant O
##itate O
relationships O
between O
exposure O
and O
safety O
and O
efficacy O
outcomes O
from O
phase O
3 O
trials O
of O
ad O
##junct O
##ive O
es O
##l O
. O
[SEP] O
[CLS] O
serial O
blood O
sampling O
for O
total O
plasma O
g O
##aa O
activity O
and O
protein O
following O
a O
##a O
in O
##fusion O
was O
performed O
for O
24 O
h O
##r O
on O
day O
1 O
of O
periods O
1 O
and O
2 O
at O
pre O
- O
dose O
( O
time O
0 O
) O
and O
at O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
, O
12 O
, O
and O
24 O
h O
##r O
after O
initiation O
of O
in O
##fusion O
. O
[SEP] O
[CLS] O
tumor O
volume O
( O
v O
) O
was O
calculated O
by O
the O
following O
formula O
: O
v O
= O
( O
w O
##2 O
##× O
##l O
) O
/ O
2 O
, O
[ O
1 O
] O
[SEP] O
[CLS] O
the O
combination O
of O
c O
##is O
##p O
##lat O
##in O
and O
5 O
- O
flu O
##oro O
##ura O
##ci O
##l O
( O
5 O
- O
f O
##u O
) O
is O
considered O
to O
be O
the O
standard O
treatment O
in O
induction O
ch O
##em O
##otherapy O
for O
patients O
with O
sq O
##ua O
##mous O
cell O
car O
##cin O
##oma O
of O
the O
head O
and O
neck O
. O
[SEP] O
[CLS] O
in O
##tra O
##vi O
##tre O
##al O
injection O
of O
anti O
- O
ve O
##g O
##f O
( O
vascular O
end O
##oth O
##eli O
##al O
growth O
factor O
) O
antibodies O
or O
anti O
##body O
fragments O
has O
been O
shown O
to O
be O
a O
highly O
effective O
treatment O
for O
neo O
##vas O
##cular O
age O
- O
related O
mac O
##ular O
de O
##gene O
##ration O
( O
wet O
am O
##d O
) O
. O
[SEP] O
[CLS] O
dry O
em O
##ul O
##sions O
consisting O
of O
red O
##is O
##pers O
##ed O
freeze O
- O
dried O
drug O
- O
milk O
formulation O
##s O
have O
been O
evaluated O
using O
re O
##con O
##st O
##itution O
in O
v O
##it O
##ro O
to O
obtain O
an O
o O
/ O
w O
em O
##ul O
##sion O
before O
administration O
for O
di O
##cum O
##aro O
##l O
( O
an O
anti O
##coa O
##gu O
##lant O
) O
( O
mac O
##her O
##as O
and O
re O
##ppa O
##s O
1986 O
##a O
) O
and O
ni O
##tro O
##fu O
##rant O
##oi O
##n O
( O
a O
b O
##act O
##eri O
##oc O
##idal O
) O
( O
mac O
##her O
##as O
and O
re O
##ppa O
##s O
1986 O
##b O
) O
respectively O
. O
[SEP] O
[CLS] O
the O
effects O
of O
na O
##lo O
##xon O
##e O
h O
##ydro O
##ch O
##lor O
##ide O
( O
na O
##l O
) O
and O
other O
op O
##iate O
antagonist O
##s O
on O
blood O
- O
ethanol O
concentration O
( O
be O
##c O
) O
in O
acute O
##ly O
- O
ethanol O
- O
into O
##xi O
##cated O
rats O
were O
examined O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
p O
##har O
##ma O
##co O
##dynamic O
##s O
and O
der O
##mal O
distribution O
of O
5 O
- O
met O
##ho O
##xy O
##ps O
##oral O
##en O
based O
on O
a O
physiological O
##ly O
based O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
to O
support O
p O
##hy O
##to O
##ther O
##ap O
##y O
using O
br O
##os O
##im O
##um O
g O
##aud O
##ich O
##aud O
##ii O
. O
[SEP] O
[CLS] O
no O
##ci O
##ceptive O
threshold O
to O
mechanical O
all O
##ody O
##nia O
was O
determined O
using O
electronic O
von O
f O
##rey O
pressure O
al O
##go O
##meter O
( O
model O
239 O
##0 O
; O
ii O
##t O
##c O
life O
science O
in O
##c O
. O
, O
woodland O
hills O
, O
ca O
, O
u O
. O
s O
. O
a O
. O
) O
on O
7 O
, O
14 O
and O
21st O
day O
. O
[SEP] O
[CLS] O
we O
used O
p O
##os O
##it O
##ron O
emission O
to O
##mo O
##graphy O
( O
pet O
) O
and O
[ O
( O
11 O
) O
c O
] O
- O
labeled O
l O
##igan O
##ds O
to O
q O
##uant O
##ify O
s O
##tri O
##ata O
##l O
and O
extra O
- O
s O
##tri O
##ata O
##l O
do O
##pa O
##mine O
- O
2 O
( O
d O
( O
2 O
) O
) O
, O
and O
co O
##rt O
##ical O
se O
##rot O
##oni O
##n O
- O
2 O
##a O
( O
5 O
- O
h O
##t O
( O
2 O
##a O
) O
) O
receptor O
o O
##cc O
##up O
##ancy O
in O
healthy O
subjects O
after O
a O
single O
dose O
, O
and O
in O
patients O
chronic O
##ally O
treated O
for O
ps O
##ych O
##osis O
. O
[SEP] O
[CLS] O
accordingly O
, O
these O
results O
indicated O
that O
op O
##ti O
##mized O
at O
##r O
s O
##ned O
##ds O
and O
n O
##s O
formulation O
##s O
improved O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
the O
water O
ins O
##ol O
##ub O
##le O
drug O
at O
##r O
. O
[SEP] O
[CLS] O
bio O
##chemistry O
: O
sodium O
, O
potassium O
, O
chloride O
, O
ma O
##gnesium O
, O
bi O
##car O
##bon O
##ate O
, O
c O
##rea O
##tin O
##ine O
, O
u O
##rea O
, O
la O
##ct O
##ate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
l O
##dh O
) O
, O
as O
##par O
##tate O
amino O
##tra O
##ns O
##fer O
##ase O
( O
as O
##t O
) O
, O
al O
##ani O
##ne O
amino O
##tra O
##ns O
##fer O
##ase O
( O
al O
##t O
) O
, O
gamma O
- O
g O
##lut O
##am O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
γ O
##gt O
) O
, O
al O
##kal O
##ine O
p O
##hos O
##pha O
##tase O
, O
total O
bi O
##li O
##ru O
##bin O
, O
album O
##in O
, O
g O
##lo O
##bul O
##in O
, O
total O
protein O
, O
calcium O
, O
p O
##hos O
##phorus O
, O
glucose O
, O
u O
##ric O
acid O
, O
total O
g O
##ly O
##cer O
##ides O
, O
high O
- O
density O
lip O
##op O
##rote O
##in O
( O
h O
##dl O
) O
, O
low O
- O
density O
lip O
##op O
##rote O
##in O
( O
l O
##dl O
) O
and O
total O
ch O
##ole O
##ster O
##ol O
. O
[SEP] O
[CLS] O
the O
bio O
- O
analytical O
method O
described O
above O
was O
used O
to O
determine O
to O
##l O
##va O
##pta O
##n O
concentrations O
in O
plasma O
followed O
by O
oral O
administration O
to O
healthy O
rabbits O
. O
[SEP] O
[CLS] O
the O
method O
is O
cost O
- O
saving O
in O
that O
it O
allows O
about O
30 O
analyses O
a O
day O
to O
be O
performed O
without O
automatic O
in O
##te O
##gra O
##tors O
, O
and O
about O
50 O
analyses O
a O
day O
with O
these O
in O
##te O
##gra O
##tors O
. O
[SEP] O
[CLS] O
eighteen O
patients O
with O
various O
ma O
##li O
##gna O
##ncies O
and O
re O
##fra O
##ctor O
##y O
ma O
##li O
##gnant O
as O
##cite O
##s O
consent O
##ed O
to O
enter O
this O
trial O
. O
[SEP] O
[CLS] O
for O
analysis O
using O
im O
##scope O
, O
α O
- O
ch O
##ca O
was O
v O
##ap O
##our O
- O
deposited O
at O
250 O
° O
##c O
onto O
the O
surface O
of O
the O
t O
##umour O
tissue O
sections O
as O
previously O
described O
##19 O
, O
and O
then O
50 O
% O
ace O
##ton O
##it O
##ril O
##e O
containing O
7 O
mg O
/ O
m O
##l O
α O
- O
ch O
##ca O
, O
1 O
µ O
##g O
/ O
m O
##l O
er O
##lot O
##ini O
##b O
d O
##6 O
, O
and O
0 O
. O
2 O
% O
t O
##fa O
was O
applied O
by O
using O
the O
image O
##p O
##re O
##p O
matrix O
deposition O
device O
( O
br O
##uke O
##r O
) O
according O
to O
manufacturer O
’ O
s O
standard O
method O
for O
α O
- O
ch O
##ca O
. O
[SEP] O
[CLS] O
the O
multi O
##disciplinary O
meeting O
should O
determine O
that O
complete O
re O
##section O
of O
the O
c O
##rl O
##m O
is O
feasible O
. O
[SEP] O
[CLS] O
in O
phase O
2 O
, O
16 O
patients O
( O
eight O
h O
##gg O
and O
eight O
dip O
##g O
) O
were O
enrolled O
; O
11 O
were O
e O
##val O
##ua O
##ble O
for O
response O
and O
five O
withdrew O
( O
three O
due O
to O
an O
##aph O
##yla O
##xi O
##s O
) O
. O
[SEP] O
[CLS] O
secondary O
p O
##har O
##ma O
##co O
##dynamic O
end O
‐ O
points O
were O
derived O
from O
the O
individual O
g O
##ir O
( O
smoothed O
) O
and O
blood O
glucose O
profiles O
at O
steady O
state O
. O
[SEP] O
[CLS] O
twelve O
men O
and O
four O
women O
, O
mean O
age O
, O
38 O
. O
6 O
+ O
- O
6 O
. O
9 O
years O
, O
received O
a O
single O
600 O
- O
mg O
oral O
dose O
of O
r O
##if O
##ap O
##ent O
##ine O
in O
an O
open O
- O
label O
, O
random O
##ized O
two O
- O
way O
, O
complete O
crossover O
study O
. O
[SEP] O
[CLS] O
thirty O
- O
two O
patients O
were O
included O
in O
a O
dose O
- O
response O
study O
, O
in O
which O
the O
patients O
received O
one O
of O
four O
doses O
of O
mi O
##va O
##cu O
##rium O
. O
[SEP] O
[CLS] O
/ O
= O
30 O
% O
dose O
es O
##cal O
##ation O
for O
i O
##rino O
##teca O
##n O
, O
when O
administered O
in O
a O
combination O
regime O
##n O
with O
c O
##is O
##p O
##lat O
##in O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
safety O
, O
and O
to O
##ler O
##ability O
of O
bay O
12 O
- O
95 O
##6 O
##6 O
and O
non O
##ster O
##oid O
##al O
anti O
- O
inflammatory O
agents O
( O
nap O
##ro O
##xen O
, O
i O
##bu O
##p O
##ro O
##fen O
) O
during O
co O
##ad O
##mini O
##stra O
##tion O
in O
patients O
with O
o O
##ste O
##oar O
##th O
##rit O
##is O
. O
[SEP] O
[CLS] O
this O
was O
mostly O
due O
to O
a O
slower O
rate O
constant O
of O
##ass O
##oc O
##iation O
( O
k O
##on O
) O
, O
in O
line O
with O
a O
hampered O
diffusion O
##th O
##rough O
the O
surface O
matrix O
of O
the O
sensor O
##chi O
##p O
. O
[SEP] O
[CLS] O
f O
##am O
##ci O
##c O
##lov O
##ir O
was O
administered O
oral O
##ly O
or O
re O
##ct O
##ally O
in O
accordance O
with O
an O
incomplete O
crossover O
design O
. O
[SEP] O
[CLS] O
the O
concentrations O
of O
cm O
##nx O
transferred O
to O
the O
u O
##ter O
##us O
and O
its O
app O
##end O
##ages O
after O
cm O
##nx O
1 O
g O
in O
##tra O
##ven O
##ous O
injection O
were O
maintained O
above O
12 O
. O
5 O
micro O
##gram O
##s O
/ O
g O
during O
first O
3 O
hours O
or O
more O
. O
[SEP] O
[CLS] O
more O
##over O
the O
p O
##h O
of O
the O
formulation O
is O
in O
the O
required O
range O
for O
the O
in O
##tra O
##ven O
##ous O
administration O
[ O
25 O
] O
. O
[SEP] O
[CLS] O
in O
these O
studies O
, O
me O
##man O
##tine O
was O
not O
actively O
transported O
by O
o O
##ct O
##1 O
, O
but O
appeared O
to O
be O
a O
substrate O
of O
o O
##ct O
##2 O
and O
o O
##at O
##p O
##2 O
##b O
##1 O
, O
with O
an O
accumulation O
of O
me O
##man O
##tine O
in O
transport O
##er O
- O
trans O
##fected O
cells O
> O
[SEP] O
[CLS] O
the O
separation O
of O
the O
ben O
##zo O
##yl O
derivatives O
was O
achieved O
on O
a O
l O
##una O
o O
##me O
##ga O
c O
##18 O
ps O
column O
, O
150 O
× O
2 O
. O
1 O
mm O
, O
1 O
. O
6 O
μ O
##m O
( O
p O
##hen O
##ome O
##nex O
) O
. O
[SEP] O
[CLS] O
all O
patients O
improved O
clinical O
##ly O
over O
16 O
+ O
- O
10 O
months O
. O
[SEP] O
[CLS] O
the O
z O
##eta O
potential O
changed O
ins O
##ign O
##ificant O
##ly O
( O
p O
> O
0 O
. O
00 O
##2 O
) O
as O
it O
depends O
on O
the O
formulation O
composition O
that O
remained O
un O
##altered O
. O
[SEP] O
[CLS] O
a O
total O
of O
40 O
##7 O
samples O
were O
collected O
. O
[SEP] O
[CLS] O
we O
conclude O
that O
the O
spatial O
resolution O
of O
our O
to O
##mo O
##graph O
reduces O
the O
apparent O
magnitude O
of O
k O
( O
3 O
) O
( O
d O
) O
in O
s O
##tri O
##at O
##um O
. O
[SEP] O
[CLS] O
the O
purpose O
of O
this O
study O
was O
to O
assess O
the O
multiple O
- O
dose O
clinical O
p O
##har O
##ma O
##cology O
of O
to O
##l O
##cap O
##one O
, O
a O
novel O
cat O
##ech O
##ol O
- O
o O
- O
met O
##hyl O
##tra O
##ns O
##fer O
##ase O
( O
com O
##t O
) O
inhibitor O
, O
in O
elderly O
subjects O
. O
[SEP] O
[CLS] O
this O
was O
followed O
by O
a O
forward O
inclusion O
and O
backward O
elimination O
procedure O
, O
with O
significance O
levels O
of O
5 O
and O
0 O
. O
1 O
% O
( O
log O
- O
likelihood O
ratio O
test O
, O
ch O
##i O
square O
distribution O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
maternal O
plasma O
profile O
following O
single O
sub O
##cut O
##aneous O
dose O
of O
50 O
mg O
/ O
kg O
on O
both O
g O
##d O
##14 O
and O
g O
##d O
##21 O
showed O
a O
mon O
##oe O
##x O
##po O
##nent O
##ial O
elimination O
pattern O
. O
[SEP] O
[CLS] O
din O
##ac O
##ic O
##li O
##b O
( O
m O
##k O
- O
79 O
##65 O
, O
formerly O
s O
##ch O
72 O
##7 O
##9 O
##65 O
, O
me O
##rc O
##k O
, O
white O
##house O
station O
, O
n O
##j O
) O
; O
p O
##ac O
##lit O
##ax O
##el O
( O
l O
##c O
laboratories O
, O
w O
##ob O
##urn O
, O
ma O
) O
; O
trip O
##to O
##lide O
( O
si O
##gma O
) O
; O
na O
##vi O
##to O
##c O
##lax O
( O
a O
##bt O
- O
26 O
##3 O
) O
( O
sell O
##eck O
chemicals O
) O
; O
k O
##dr O
inhibitor O
b O
[ O
19 O
] O
( O
me O
##rc O
##k O
, O
white O
##house O
station O
, O
n O
##j O
) O
. O
[SEP] O
[CLS] O
a O
simple O
liquid O
ch O
##roma O
##tography O
tandem O
mass O
s O
##pect O
##rome O
##try O
method O
was O
developed O
and O
valid O
##ated O
according O
to O
the O
guidelines O
of O
the O
us O
food O
and O
drug O
administration O
and O
the O
euro O
##pe O
##an O
medicines O
agency O
for O
a O
simultaneous O
q O
##uant O
##ification O
of O
le O
##vet O
##ira O
##ce O
##tam O
( O
le O
##v O
) O
and O
its O
meta O
##bol O
##ite O
, O
u O
##c O
##b O
l O
##0 O
##5 O
##7 O
in O
the O
plasma O
of O
patients O
. O
[SEP] O
[CLS] O
further O
, O
the O
24 O
- O
h O
u O
##ge O
of O
w O
##t O
mice O
did O
not O
show O
a O
significant O
response O
to O
the O
1 O
mg O
/ O
kg O
dose O
of O
l O
##p O
- O
92 O
##5 O
##21 O
##9 O
, O
and O
the O
response O
to O
the O
60 O
mg O
/ O
kg O
dose O
, O
which O
was O
68 O
± O
15 O
% O
of O
ma O
##ximal O
, O
was O
significantly O
greater O
than O
vehicle O
- O
treated O
control O
values O
but O
was O
still O
significantly O
less O
than O
ma O
##ximal O
values O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
ace O
##ta O
##zo O
##lam O
##ide O
tablets O
. O
[SEP] O
[CLS] O
however O
, O
the O
number O
of O
he O
##pa O
##to O
##cy O
##tes O
isolated O
per O
gram O
of O
per O
##fused O
tissue O
was O
five O
##fold O
higher O
than O
that O
reported O
by O
s O
##te O
##fan O
##ski O
et O
al O
. O
( O
2013 O
) O
( O
n O
= O
9 O
) O
but O
five O
##fold O
lower O
than O
in O
the O
study O
by O
b O
##aka O
##la O
et O
al O
. O
( O
2003 O
) O
. O
[SEP] O
[CLS] O
the O
duration O
of O
therapy O
was O
also O
assessed O
. O
[SEP] O
[CLS] O
no O
me O
##as O
##urable O
plasma O
concentrations O
of O
the O
n O
##1 O
- O
g O
##lu O
##cu O
##ron O
##ides O
from O
su O
##lf O
##adi O
##met O
##ho O
##xin O
##e O
are O
found O
in O
plasma O
. O
[SEP] O
[CLS] O
since O
m O
##3 O
##g O
has O
been O
shown O
to O
be O
anti O
##ana O
##lge O
##si O
##c O
and O
is O
the O
only O
meta O
##bol O
##ite O
of O
m O
##or O
##phine O
in O
the O
rat O
, O
it O
is O
concluded O
that O
the O
levels O
of O
this O
meta O
##bol O
##ite O
may O
regulate O
the O
anal O
##ges O
##ic O
effect O
of O
m O
##or O
##phine O
in O
the O
rat O
. O
[SEP] O
[CLS] O
four O
patients O
had O
grade O
3 O
toxic O
##ities O
at O
longer O
in O
##fusion O
schedules O
. O
[SEP] O
[CLS] O
the O
compound O
- O
dependent O
m O
##s O
/ O
m O
##s O
parameters O
for O
anal O
##yte O
##s O
in O
the O
m O
##rm O
mode O
are O
summarized O
in O
table O
1 O
. O
[SEP] O
[CLS] O
the O
mean O
( O
± O
s O
##d O
) O
c B-PK
< I-PK
sub I-PK
> I-PK
ma I-PK
##x I-PK
< I-PK
/ I-PK
sub I-PK
> I-PK
of O
the O
test O
and O
the O
reference O
formulation O
were O
141 O
. O
401 O
± O
29 O
. O
44 O
##7 O
ng O
/ O
m O
##l O
and O
138 O
. O
83 O
##7 O
± O
31 O
. O
39 O
##2 O
ng O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
data O
of O
each O
patient O
are O
stored O
on O
the O
hospital O
server O
and O
protected O
by O
a O
fire O
##wall O
system O
with O
password O
access O
. O
[SEP] O
[CLS] O
the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
si O
##m O
##vas O
##tat O
##in O
and O
its O
h O
##ydro O
##ly O
##sat O
##e O
si O
##m O
##vas O
##tat O
##in O
acid O
in O
a O
rat O
model O
of O
type O
2 O
diabetes O
. O
[SEP] O
[CLS] O
the O
c O
##s O
##f O
level O
was O
below O
the O
limit O
of O
detection O
except O
in O
the O
high O
dose O
group O
. O
[SEP] O
[CLS] O
the O
detection O
of O
anal O
##yte O
##s O
was O
achieved O
by O
electro O
##sp O
##ray O
ion O
##ization O
( O
es O
##i O
) O
in O
the O
positive O
mode O
with O
the O
appropriate O
m O
##s O
/ O
m O
##s O
transitions O
, O
if O
necessary O
. O
[SEP] O
[CLS] O
time O
- O
dependent O
se O
##ns O
##iti O
##zation O
to O
t O
##ria O
##zo O
##lam O
? O
[SEP] O
[CLS] O
it O
increased O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
to O
258 O
. O
7 O
+ O
- O
54 O
. O
2 O
mm O
##ol O
for O
the O
2 O
days O
of O
dos O
##age O
and O
the O
following O
day O
. O
[SEP] O
[CLS] O
to O
reflect O
the O
actual O
meal O
time O
, O
eh O
##c O
models O
with O
two O
or O
more O
meal O
times O
were O
tested O
. O
[SEP] O
[CLS] O
the O
in O
##hibition O
of O
ad O
##p O
- O
induced O
plate O
##let O
a O
##gg O
##regation O
of O
plate O
##let O
- O
rich O
plasma O
( O
p O
##rp O
) O
was O
measured O
in O
response O
to O
5 O
μ O
##m O
ad O
##p O
as O
described O
elsewhere O
( O
m O
##ull O
##er O
et O
al O
. O
, O
2003 O
; O
g O
##ei O
##ger O
et O
al O
. O
, O
2005 O
) O
. O
[SEP] O
[CLS] O
maximum O
changes O
in O
b O
##p O
were O
observed O
on O
average O
6 O
hours O
after O
dos O
##ing O
with O
a O
com O
##pen O
##sat O
##ory O
p O
##r O
increase O
. O
[SEP] O
[CLS] O
each O
blank O
sample O
was O
tested O
for O
any O
interference O
, O
also O
the O
ones O
associated O
with O
th O
##io O
##pent O
##al O
, O
using O
the O
proposed O
extraction O
procedure O
and O
ch O
##roma O
##to O
##graphic O
/ O
mass O
s O
##pect O
##rome O
##tric O
conditions O
and O
compared O
with O
those O
obtained O
with O
an O
a O
##que O
##ous O
solution O
of O
the O
anal O
##yte O
at O
a O
concentration O
near O
the O
lower O
limit O
of O
q O
##uant O
##ification O
( O
ll O
##o O
##q O
) O
. O
[SEP] O
[CLS] O
the O
hp O
##l O
##c O
method O
was O
cross O
- O
valid O
##ated O
with O
a O
previously O
reported O
g O
##c O
method O
by O
the O
analysis O
of O
73 O
plasma O
samples O
spike O
##d O
with O
various O
concentrations O
of O
s O
##ch O
39 O
##16 O
##6 O
and O
s O
##ch O
40 O
##8 O
##53 O
. O
[SEP] O
[CLS] O
the O
kinetic O
##s O
of O
binding O
of O
111 O
##in O
- O
not O
##a O
- O
p O
##eg O
##n O
- O
r O
##m O
##26 O
to O
the O
p O
##c O
- O
3 O
cells O
was O
measured O
in O
real O
- O
time O
at O
r O
##t O
using O
l O
##igan O
##dt O
##race O
##r O
instruments O
( O
ridge O
##view O
instruments O
a O
##b O
, O
up O
##ps O
##ala O
, O
s O
##wed O
##en O
) O
, O
as O
described O
previously O
[ O
42 O
] O
. O
[SEP] O
[CLS] O
the O
disappearance B-PK
rate I-PK
of O
p O
##hen O
##ace O
##tin O
tended O
to O
be O
lower O
in O
the O
presence O
of O
ho O
##no O
##ki O
##ol O
and O
ma O
##gno O
##lo O
##l O
of O
≥ O
##2 O
μ O
##m O
than O
in O
their O
absence O
. O
[SEP] O
[CLS] O
mon O
##oc O
##lon O
##al O
antibodies O
( O
ma O
##bs O
) O
against O
high O
- O
molecular O
- O
weight O
me O
##lan O
##oma O
- O
associated O
anti O
##gen O
( O
h O
##m O
##w O
- O
ma O
##a O
) O
have O
been O
used O
in O
v O
##ivo O
to O
target O
me O
##lan O
##oma O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
electro O
##phy O
##sio O
##logical O
effects O
of O
so O
##tal O
##ol O
h O
##ydro O
##ch O
##lor O
##ide O
in O
horses O
. O
[SEP] O
[CLS] O
static O
fuzzy O
locally O
adaptive O
bay O
##esi O
##an O
( O
fl O
##ab O
) O
volumes O
correspond O
##ed O
best O
with O
path O
##ology O
volumes O
( O
in O
##tra O
##c O
##lass O
correlation O
coefficient O
, O
0 O
. O
72 O
; O
p O
< O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
min O
/ O
m O
##l O
) O
by O
g O
##g O
##9 O
##18 O
( O
1 O
, O
73 O
##0 O
+ O
- O
270 O
ng O
. O
[SEP] O
[CLS] O
in O
three O
open O
, O
random O
##ized O
, O
cross O
- O
over O
sessions O
with O
> O
or O
= O
14 O
days O
wash O
##out O
, O
l O
##t O
##g O
100 O
mg O
and O
o O
##x O
##c O
600 O
mg O
were O
given O
oral O
##ly O
, O
each O
to O
6 O
subjects O
. O
[SEP] O
[CLS] O
the O
objective O
of O
this O
phase O
i O
, O
open O
- O
label O
single O
- O
dose O
study O
was O
to O
determine O
if O
mild O
or O
moderate O
he O
##pa O
##tic O
imp O
##air O
##ment O
alter O
##s O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
mi O
##rog O
##aba O
##lin O
. O
[SEP] O
[CLS] O
no O
correlation O
was O
found O
between O
m O
##dr O
##1 O
m O
##rna O
expression O
and O
re B-PK
##nal I-PK
clearance I-PK
of O
di O
##c O
##lo O
##xa O
##ci O
##llin O
. O
[SEP] O
[CLS] O
for O
trim O
##eth O
##op O
##rim O
concentrations O
, O
p O
##ks O
were O
also O
found O
to O
be O
best O
described O
by O
a O
one O
‐ O
compartment O
model O
( O
table O
##2 O
) O
. O
[SEP] O
[CLS] O
c O
##es O
##1 O
gene O
variation O
only O
partially O
explains O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
var O
##iability O
. O
[SEP] O
[CLS] O
according O
to O
the O
da O
##rp O
##a O
standard O
, O
a O
highly O
effective O
re O
##age O
##nt O
retains O
> O
85 O
% O
activity O
after O
heating O
at O
70 O
##° O
##c O
for O
1 O
h O
. O
5 O
as O
an O
initial O
test O
of O
the O
thermal O
effect O
on O
the O
activity O
of O
bi O
‐ O
l O
##pa O
, O
we O
performed O
an O
el O
##isa O
before O
and O
after O
heating O
at O
70 O
##° O
##c O
for O
1 O
h O
. O
as O
shown O
in O
figure O
6 O
##b O
, O
the O
k O
##d O
for O
un O
##heat O
##ed O
bi O
‐ O
l O
##pa O
is O
216 O
± O
7 O
nm O
, O
whereas O
the O
k O
##d O
after O
an O
hour O
is O
28 O
##3 O
nm O
± O
27 O
nm O
, O
suggesting O
ins O
##ign O
##ificant O
reduction O
in O
k O
##d O
after O
the O
re O
##age O
##nt O
is O
heated O
, O
sur O
##passing O
the O
70 O
##° O
##c O
for O
1 O
h O
precedence O
. O
[SEP] O
[CLS] O
p O
##k O
assessment O
was O
conducted O
on O
day O
1 O
at O
0 O
, O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
9 O
, O
12 O
and O
24 O
hours O
post O
- O
dose O
and O
on O
day O
11 O
at O
0 O
, O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
9 O
, O
12 O
and O
24 O
hours O
post O
- O
dose O
. O
[SEP] O
[CLS] O
this O
hp O
##l O
##c O
method O
is O
useful O
for O
the O
analysis O
and O
evaluation O
of O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
v O
##n O
/ O
14 O
- O
1 O
##ra O
in O
rats O
. O
[SEP] O
[CLS] O
do O
##ce O
##ta O
##xe O
##l O
and O
v O
##ino O
##rel O
##bine O
were O
given O
at O
80 O
mg O
/ O
m O
##2 O
and O
20 O
mg O
/ O
m O
##2 O
i O
. O
v O
. O
, O
respectively O
, O
on O
day O
1 O
every O
3 O
weeks O
. O
[SEP] O
[CLS] O
there O
were O
no O
further O
differences O
( O
p O
> O
0 O
. O
1 O
) O
. O
[SEP] O
[CLS] O
b O
##g O
##9 O
##9 O
##28 O
was O
well O
tolerate O
##d O
. O
[SEP] O
[CLS] O
consequently O
, O
the O
m O
##pe O
##g O
##2 O
##k O
- O
b O
- O
t O
##ria O
polymer O
##s O
would O
be O
another O
promising O
carrier O
for O
h O
##ydro O
##phobic O
anti O
- O
cancer O
drugs O
delivery O
. O
[SEP] O
[CLS] O
unlike O
car O
##ba O
##ma O
##ze O
##pine O
, O
la O
##mot O
##rig O
##ine O
is O
ads O
##or O
##bed O
to O
the O
root O
and O
undergo O
##es O
ion O
trapping O
in O
root O
cells O
thus O
its O
trans O
##location O
to O
the O
shoots O
is O
limited O
. O
[SEP] O
[CLS] O
in O
##c O
. O
s O
##t O
. O
lo O
##ui O
##s O
. O
[SEP] O
[CLS] O
no O
d O
##lts O
occurred O
during O
the O
21 O
- O
day O
d O
##lt O
assessment O
period O
, O
so O
the O
m O
##t O
##d O
was O
not O
reached O
. O
[SEP] O
[CLS] O
elimination O
was O
reduced O
in O
comparison O
with O
healthy O
volunteers O
: O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
beta I-PK
510 O
+ O
- O
158 O
min O
with O
a O
total B-PK
area I-PK
under I-PK
the I-PK
curve I-PK
of O
18 O
. O
2 O
+ O
- O
10 O
. O
3 O
mg O
x O
h O
/ O
l O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
controlled O
- O
release O
polymer O
##s O
in O
the O
sub O
##ara O
##ch O
##no O
##id O
space O
after O
sub O
##ara O
##ch O
##no O
##id O
hem O
##or O
##r O
##hage O
in O
rabbits O
. O
[SEP] O
[CLS] O
the O
model O
predicted O
an O
approximate O
60 O
% O
decrease O
for O
the O
mean O
estimates O
of O
e O
##f O
##v O
apparent B-PK
oral I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
in O
p O
##ediatric O
subjects O
who O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
156 O
##31 O
##gt O
substitution O
( O
156 O
##31 O
##tt O
) O
relative O
to O
that O
in O
p O
##ediatric O
subjects O
who O
did O
not O
carry O
the O
substitution O
on O
either O
all O
##ele O
( O
156 O
##31 O
##gg O
) O
and O
an O
approximate O
25 O
% O
decrease O
in O
p O
##ediatric O
subjects O
who O
carried O
the O
substitution O
on O
one O
all O
##ele O
( O
156 O
##31 O
##gt O
) O
relative O
to O
that O
in O
subjects O
who O
carried O
the O
wild O
type O
. O
[SEP] O
[CLS] O
mean O
ca O
##sp O
##of O
##ung O
##in O
t B-PK
##rough I-PK
and O
peak B-PK
levels I-PK
were O
3 O
. O
73 O
and O
11 O
. O
95 O
micro O
##g O
/ O
m O
##l O
. O
these O
are O
comparable O
to O
previously O
reported O
ones O
. O
[SEP] O
[CLS] O
the O
exact O
role O
of O
the O
s O
##v O
##2 O
##a O
protein O
is O
not O
fully O
understood O
; O
it O
is O
thought O
to O
participate O
in O
the O
p O
##hy O
##sio O
##log O
##ic O
functioning O
of O
the O
s O
##yna O
##ptic O
ve O
##si O
##cle O
. O
19 O
its O
role O
in O
e O
##pile O
##psy O
is O
supported O
by O
the O
fact O
that O
s O
##v O
##2 O
##a O
knock O
- O
out O
mice O
develop O
seizure O
##s O
soon O
after O
birth O
and O
usually O
die O
within O
3 O
weeks O
. O
21 O
further O
##more O
, O
the O
affinity O
of O
various O
compounds O
to O
the O
s O
##v O
##2 O
##a O
binding O
site O
co O
##rrel O
##ates O
strongly O
with O
their O
anti O
- O
seizure O
pot O
##ency O
in O
the O
audio O
##genic O
e O
##pile O
##psy O
mouse O
model O
. O
19 O
[SEP] O
[CLS] O
the O
mean O
absolute O
recover O
##ies O
of O
two O
anal O
##yte O
##s O
were O
> O
90 O
% O
. O
[SEP] O
[CLS] O
r O
##ito O
##na O
##vir O
powder O
formulation O
administered O
in O
chocolate O
milk O
, O
pu O
##dding O
, O
infant O
formula O
or O
apple O
sauce O
was O
bio O
##e O
##qui O
##valent O
to O
the O
powder O
formulation O
administered O
in O
water O
. O
[SEP] O
[CLS] O
the O
sample O
preparation O
for O
ca O
##li O
##bra O
##tion O
curves O
was O
obtained O
by O
freshly O
spike O
##d O
plasma O
samples O
with O
stock O
solution O
of O
r O
##hein O
at O
concentration O
ranges O
of O
0 O
. O
05 O
– O
2 O
. O
5 O
µ O
##g O
/ O
m O
##l O
. O
a O
blank O
plasma O
sample O
was O
also O
analyzed O
to O
confirm O
absence O
of O
interference O
##s O
. O
[SEP] O
[CLS] O
this O
is O
the O
most O
comprehensive O
p O
##k O
study O
to O
date O
in O
subjects O
with O
hereditary O
f O
##x O
deficiency O
. O
[SEP] O
[CLS] O
multiple O
linear O
re O
##gression O
models O
showed O
significant O
correlation O
##s O
between O
parameters O
of O
met O
##hot O
##re O
##xa O
##te O
clearance B-PK
and O
certain O
re O
##nal O
function O
tests O
. O
[SEP] O
[CLS] O
however O
, O
be O
##rber O
##ine O
release O
took O
several O
hours O
, O
indicating O
that O
certain O
resistance O
was O
provided O
by O
the O
dial O
##ys O
##is O
bag O
. O
[SEP] O
[CLS] O
parameters O
such O
as O
recovery O
, O
linear O
##ity O
, O
accuracy O
, O
precision O
, O
select O
##ivity O
, O
matrix O
effect O
and O
stability O
of O
samples O
were O
investigated O
. O
[SEP] O
[CLS] O
the O
self O
‐ O
mediated O
, O
time O
‐ O
dependent O
c O
##y O
##p O
##2 O
##c O
##19 O
in O
##hibition O
by O
o O
##me O
##pra O
##zo O
##le O
suggests O
that O
multiple O
doses O
of O
this O
agent O
are O
not O
recommended O
in O
drug O
– O
drug O
interaction O
studies O
, O
unless O
there O
is O
sufficient O
wash O
##out O
time O
. O
[SEP] O
[CLS] O
as O
a O
consequence O
, O
the O
ni O
##r O
spat O
##iot O
##em O
##por O
##al O
bio O
##ima O
##ging O
in O
v O
##ivo O
with O
dual O
flu O
##ores O
##cence O
channels O
allows O
the O
pro O
##dr O
##ug O
release O
profile O
to O
be O
extracted O
precisely O
, O
particularly O
in O
visual O
##izing O
drug O
- O
released O
information O
from O
complex O
biological O
systems O
such O
as O
mice O
, O
thereby O
providing O
a O
unique O
opportunity O
to O
take O
insight O
into O
the O
relationship O
between O
the O
##rano O
##sis O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
administration O
of O
et O
##ra O
##vir O
##ine O
in O
a O
fast O
##ed O
state O
resulted O
in O
51 O
% O
lower O
mean O
exposure O
compared O
with O
dos O
##ing O
after O
a O
standard O
breakfast O
. O
[SEP] O
[CLS] O
a O
summary O
of O
the O
i O
##pa O
data O
obtained O
from O
study O
i O
and O
study O
ii O
is O
presented O
in O
table O
3 O
. O
[SEP] O
[CLS] O
m O
##rz O
2 O
/ O
57 O
##9 O
blocked O
steady O
- O
state O
inward O
current O
responses O
of O
culture O
##d O
hip O
##po O
##cam O
##pal O
ne O
##uron O
##es O
to O
nm O
##da O
with O
an O
i B-PK
##c I-PK
##50 I-PK
of O
1 O
. O
11 O
micro O
##m O
at O
- O
70 O
m O
##v O
. O
much O
higher O
concentrations O
of O
m O
##rz O
2 O
/ O
57 O
##9 O
blocked O
voltage O
- O
activated O
ca O
##2 O
+ O
channels O
with O
an O
i B-PK
##c I-PK
##50 I-PK
of O
340 O
micro O
##m O
. O
m O
##rz O
2 O
/ O
57 O
##9 O
( O
10 O
micro O
##m O
) O
reduced O
peak O
inward O
current O
responses O
of O
ne O
##uron O
##al O
ni O
##cot O
##ini O
##c O
receptors O
only O
to O
72 O
. O
3 O
% O
of O
control O
. O
[SEP] O
[CLS] O
the O
absorption O
and O
ex O
##cre O
##tion O
of O
n O
##s O
- O
49 O
( O
( O
r O
) O
- O
( O
- O
) O
- O
3 O
' O
- O
( O
2 O
- O
amino O
- O
1 O
- O
h O
##ydro O
##xy O
##eth O
##yl O
) O
- O
4 O
' O
- O
flu O
##oro O
##met O
##hane O
##sul O
##fo O
##nan O
##ili O
##de O
h O
##ydro O
##ch O
##lor O
##ide O
, O
ca O
##s O
137 O
##43 O
##1 O
- O
04 O
- O
0 O
) O
, O
a O
p O
##hen O
##eth O
##yla O
##mine O
class O
alpha O
1 O
##a O
- O
ad O
##ren O
##oc O
##ept O
##or O
ago O
##nist O
, O
were O
studied O
in O
rats O
after O
a O
single O
administration O
of O
14 O
##c O
- O
n O
##s O
- O
49 O
. O
[SEP] O
[CLS] O
statistical O
analysis O
of O
quantitative O
a O
##ero O
##bic O
and O
an O
##ae O
##ro O
##bic O
cultures O
of O
f O
##ec O
##es O
was O
performed O
, O
and O
beta O
- O
la O
##ct O
##ama O
##se O
activity O
was O
determined O
. O
[SEP] O
[CLS] O
the O
study O
drugs O
were O
administered O
after O
a O
> O
or O
= O
12 O
- O
hour O
( O
overnight O
) O
fast O
. O
[SEP] O
[CLS] O
last O
##ly O
, O
a O
combination O
therapy O
experiment O
with O
two O
drugs O
showing O
different O
half B-PK
- I-PK
lives I-PK
was O
conducted O
using O
is O
##onia O
##zi O
##d O
at O
cm B-PK
##ax I-PK
= O
1 O
, O
200 O
ng O
/ O
m O
##l O
, O
t B-PK
##max I-PK
= O
2 O
. O
2 O
hour O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
4 O
. O
7 O
hour O
and O
p O
##yra O
##zin O
##ami O
##de O
at O
cm B-PK
##ax I-PK
= O
28 O
, O
900 O
ng O
/ O
m O
##l O
, O
t B-PK
##max I-PK
= O
2 O
. O
2 O
hour O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
8 O
. O
7 O
hour O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
efficacy O
of O
high O
- O
dose O
met O
##oc O
##lop O
##ram O
##ide O
given O
by O
continuous O
in O
##fusion O
for O
the O
control O
of O
c O
##yt O
##oto O
##xi O
##c O
drug O
- O
induced O
vomit O
##ing O
. O
[SEP] O
[CLS] O
an O
##ae O
##mia O
led O
to O
rib O
##avi O
##rin O
dose O
reduction O
in O
five O
patients O
. O
[SEP] O
[CLS] O
the O
mat O
##la O
##b O
code O
for O
the O
simulation O
is O
provided O
in O
the O
supplement O
##ary O
material O
online O
. O
[SEP] O
[CLS] O
this O
resulted O
in O
excellent O
predictions O
of O
the O
in O
v O
##ivo O
oral O
plasma O
concentration O
- O
time O
profiles O
, O
as O
compared O
to O
using O
the O
traditional O
inputs O
of O
the O
##rm O
##ody O
##nam O
##ic O
p O
##h O
- O
so O
##lub O
##ility O
profiles O
. O
[SEP] O
[CLS] O
camp O
##to O
##the O
##cin O
showed O
strong O
c O
##yt O
##oto O
##xi O
##city O
against O
a O
variety O
of O
t O
##umour O
types O
in O
v O
##it O
##ro O
and O
in O
v O
##ivo O
( O
wall O
and O
wa O
##ni O
, O
1996 O
; O
ch O
##ab O
##ot O
, O
1997 O
) O
. O
[SEP] O
[CLS] O
less O
potent O
but O
more O
water O
soluble O
compounds O
such O
as O
13 O
##h O
( O
i B-PK
##c I-PK
##50 I-PK
= O
60 O
nm O
) O
and O
13 O
##n O
( O
i B-PK
##c I-PK
##50 I-PK
= O
70 O
nm O
) O
are O
absorbed O
following O
oral O
dos O
##ing O
and O
achieve O
plasma O
levels O
significantly O
in O
excess O
of O
their O
i B-PK
##c I-PK
##50 I-PK
for O
a O
##cat O
in O
##hibition O
. O
[SEP] O
[CLS] O
bitch O
##es O
were O
dose O
##d O
again O
once O
on O
day O
28 O
before O
the O
pu O
##ps O
were O
suck O
##ling O
. O
[SEP] O
[CLS] O
the O
mean O
re O
##gression O
coefficient O
was O
more O
than O
0 O
. O
99 O
. O
[SEP] O
[CLS] O
in O
general O
, O
h O
##dl O
‐ O
c O
levels O
increased O
in O
a O
dose O
‐ O
dependent O
manner O
for O
both O
r O
##n O
##31 O
##7 O
and O
b O
##oc O
##oc O
##iz O
##uma O
##b O
. O
[SEP] O
[CLS] O
these O
studies O
indicated O
in O
particular O
that O
: O
( O
1 O
) O
the O
injection O
of O
a O
minimal O
neutral O
##izing O
anti O
##ven O
##om O
dose O
is O
required O
for O
a O
complete O
and O
permanent O
neutral O
##ization O
of O
circulating O
venom O
anti O
##gens O
; O
this O
dose O
is O
named O
minimal O
( O
threshold O
) O
e O
##ff O
##ica O
##cious O
anti O
##ven O
##om O
dose O
; O
( O
2 O
) O
the O
in O
##tra O
##mus O
##cular O
route O
is O
not O
the O
most O
appropriate O
way O
for O
anti O
##ven O
##om O
injection O
; O
and O
( O
3 O
) O
a O
delayed O
anti O
##ven O
##om O
im O
##mu O
##not O
##her O
##ap O
##y O
remains O
e O
##ff O
##ica O
##cious O
especially O
on O
the O
neutral O
##ization O
of O
the O
remaining O
circulating O
venom O
. O
[SEP] O
[CLS] O
for O
the O
p O
##k O
- O
p O
##d O
analysis O
, O
patients O
were O
included O
if O
they O
fulfilled O
all O
of O
the O
criteria O
for O
the O
p O
##k O
analysis O
, O
as O
well O
as O
the O
following O
conditions O
: O
a O
history O
of O
treatment O
with O
v O
##pa O
for O
one O
year O
or O
longer O
; O
not O
taking O
any O
drugs O
that O
may O
affect O
the O
liver O
function O
, O
except O
for O
anti O
##ep O
##ile O
##ptic O
agents O
; O
and O
no O
history O
of O
either O
viral O
or O
alcoholic O
liver O
disease O
. O
[SEP] O
[CLS] O
figure O
3 O
##b O
, O
c O
demonstrated O
that O
be O
##va O
##ci O
##zu O
##ma O
##b O
clearance B-PK
was O
significantly O
faster O
( O
p O
= O
0 O
. O
00 O
##14 O
) O
in O
patients O
without O
prior O
gas O
##tre O
##ct O
##omy O
( O
median O
= O
4 O
. O
72 O
m O
##l O
/ O
day O
/ O
kg O
, O
n O
= O
120 O
) O
than O
those O
with O
gas O
##tre O
##ct O
##omy O
( O
median O
= O
3 O
. O
75 O
m O
##l O
/ O
day O
/ O
kg O
, O
n O
= O
42 O
) O
with O
a O
ratio O
of O
geometric O
means O
of O
1 O
. O
19 O
( O
95 O
% O
c O
##i O
= O
1 O
. O
07 O
to O
1 O
. O
32 O
) O
. O
[SEP] O
[CLS] O
after O
an O
overnight O
fast O
, O
g O
##lu O
##cos O
##amine O
h O
##c O
##l O
( O
20 O
mg O
/ O
kg O
of O
body O
weight O
) O
was O
administered O
by O
either O
na O
##so O
##gas O
##tric O
( O
ng O
) O
in O
##tub O
##ation O
or O
in O
##tra O
##ven O
##ous O
( O
i O
##v O
) O
injection O
. O
[SEP] O
[CLS] O
the O
authors O
confirm O
that O
all O
ongoing O
and O
related O
trials O
for O
this O
drug O
/ O
intervention O
are O
registered O
. O
[SEP] O
[CLS] O
second O
, O
heat O
may O
increase O
the O
mi O
##so O
- O
al O
##ky O
##lating O
agent O
interactions O
, O
which O
are O
independent O
of O
pre O
- O
in O
##cu O
##bation O
time O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
trans O
##bu O
##cca O
##l O
t O
therapy O
was O
sufficient O
to O
maintain O
normal O
sexual O
function O
while O
mini O
##mizing O
the O
total O
time O
of O
exposure O
to O
elevated O
circulating O
serum O
t O
levels O
. O
[SEP] O
[CLS] O
p O
##x O
- O
86 O
##6 O
exhibited O
in O
v O
##ivo O
anti O
##tum O
##or O
activity O
against O
s O
. O
c O
. O
o O
##v O
##car O
- O
3 O
human O
o O
##var O
##ian O
cancer O
and O
a O
- O
54 O
##9 O
human O
lung O
cancer O
x O
##eno O
##gra O
##fts O
in O
im O
##mu O
##no O
##de O
##ficient O
mice O
with O
log O
cell O
kills O
up O
to O
1 O
. O
2 O
. O
[SEP] O
[CLS] O
put O
##ative O
therapeutic O
me O
##lat O
##oni O
##n O
levels O
were O
reached O
8 O
h O
after O
hi O
( O
104 O
increase O
from O
base O
##line O
; O
~ O
15 O
- O
30 O
mg O
/ O
l O
) O
. O
[SEP] O
[CLS] O
the O
micro O
##dos O
##e O
and O
regular O
dose O
of O
o O
##me O
##pra O
##zo O
##le O
were O
again O
administered O
on O
days O
8 O
and O
9 O
( O
figure O
1 O
) O
. O
[SEP] O
[CLS] O
the O
lower O
limit O
of O
q O
##uant O
##itation O
( O
ll O
##o O
##q O
) O
was O
calculated O
( O
n O
= O
12 O
) O
as O
the O
lowest O
drug O
concentration O
on O
the O
standard O
curve O
that O
could O
be O
q O
##uant O
##itated O
with O
c O
##v O
and O
relative O
error O
not O
exceeding O
20 O
% O
, O
and O
recovery O
between O
20 O
and O
80 O
% O
of O
nominal O
value O
( O
11 O
, O
12 O
) O
. O
[SEP] O
[CLS] O
the O
average O
values O
of O
the O
estimated O
parameters O
by O
the O
boots O
##tra O
##p O
method O
resembled O
the O
final O
estimates O
of O
the O
population O
p O
##k O
parameters O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
subjects O
were O
recreational O
drug O
users O
who O
reported O
having O
used O
2 O
##c O
- O
b O
at O
least O
once O
in O
their O
lives O
. O
[SEP] O
[CLS] O
mon O
##oc O
##lon O
##al O
anti O
##body O
216 O
targeting O
was O
determined O
with O
an O
anti O
- O
idiot O
##y O
##pic O
anti O
##body O
to O
mon O
##oc O
##lon O
##al O
anti O
##body O
216 O
and O
preliminary O
efficacy O
was O
analyzed O
by O
changes O
in O
peripheral O
blood O
blast O
##s O
. O
[SEP] O
[CLS] O
the O
concentration O
of O
bi O
##le O
salts O
in O
plasma O
was O
increased O
by O
2 O
. O
1 O
fold O
in O
ch O
##ole O
##static O
rats O
. O
[SEP] O
[CLS] O
single O
- O
dose O
administration O
of O
can O
##na O
##bid O
##iol O
oral O
solution O
showed O
inter O
- O
individual O
var O
##iability O
with O
differences O
in O
systemic O
exposure O
between O
co O
##hor O
##ts O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
study O
noted O
that O
p O
##hen O
##ob O
##ar O
##bit O
##al O
dos O
##ing O
should O
take O
into O
account O
the O
patient O
’ O
s O
fat O
- O
free O
mass O
, O
post O
##men O
##st O
##ru O
##al O
age O
, O
serum O
c O
##rea O
##tin O
##ine O
, O
and O
age O
in O
years O
. O
[SEP] O
[CLS] O
during O
continuous O
war O
##fari O
##n O
treatment O
( O
mean O
daily O
dose O
5 O
. O
3 O
mg O
, O
range O
2 O
. O
5 O
- O
9 O
. O
4 O
mg O
) O
, O
te O
##rod O
##ili O
##ne O
or O
place O
##bo O
was O
given O
for O
two O
weeks O
in O
a O
random O
##ized O
and O
double O
- O
blind O
fashion O
, O
and O
then O
the O
drugs O
were O
crossed O
over O
and O
given O
for O
another O
two O
weeks O
. O
[SEP] O
[CLS] O
safety O
evaluation O
##s O
included O
physical O
examinations O
, O
physician O
ratings O
of O
a O
##es O
, O
safety O
laboratory O
tests O
, O
vital O
signs O
, O
12 O
- O
lead O
e O
##c O
##g O
and O
e O
##c O
##g O
te O
##lem O
##et O
##ry O
from O
- O
1 O
h O
to O
24 O
h O
. O
whole O
blood O
concentrations O
of O
i O
##bo O
##gai O
##ne O
and O
nor O
##ib O
##oga O
##ine O
were O
measured O
using O
a O
valid O
##ated O
g O
##c O
/ O
m O
##s O
method O
with O
de O
##uter O
##ated O
internal O
standards O
( O
hear O
##n O
et O
al O
. O
, O
1995 O
) O
. O
[SEP] O
[CLS] O
there O
were O
, O
however O
, O
a O
few O
individuals O
with O
a O
prolonged O
elimination O
phase O
. O
[SEP] O
[CLS] O
as O
expected O
, O
no O
b O
##l O
##q O
data O
were O
found O
at O
2 O
##hr O
and O
24 O
##hr O
. O
[SEP] O
[CLS] O
a O
total O
of O
0 O
. O
05 O
m O
##l O
of O
s O
##r O
- O
03 O
##7 O
##9 O
solution O
was O
administered O
per O
spray O
using O
this O
container O
. O
[SEP] O
[CLS] O
several O
minor O
meta O
##bol O
##ites O
were O
seen O
that O
ch O
##roma O
##to O
##graph O
##ed O
in O
the O
di O
##hy O
##dr O
##ox O
##y O
acid O
region O
as O
judged O
by O
hp O
##l O
##c O
and O
t O
##l O
##c O
. O
[SEP] O
[CLS] O
third O
, O
b O
##f O
( O
50 O
mg O
/ O
kg O
) O
was O
administered O
to O
rats O
on O
day O
15 O
of O
pregnancy O
to O
determine O
whether O
d O
##b O
##f O
could O
cross O
the O
place O
##nta O
. O
[SEP] O
[CLS] O
during O
a O
cross O
- O
over O
study O
, O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
et O
##hin O
##yle O
##stra O
##dio O
##l O
( O
e O
##e O
) O
and O
3 O
- O
k O
##eto O
- O
des O
##og O
##est O
##rel O
( O
k O
##d O
##g O
) O
were O
investigated O
on O
days O
7 O
and O
22 O
of O
one O
cycle O
of O
treatment O
with O
two O
bi O
##pha O
##si O
##c O
formulation O
##s O
containing O
50 O
micro O
##gram O
##s O
e O
##e O
( O
7 O
tablets O
) O
and O
50 O
micro O
##gram O
##s O
e O
##e O
+ O
125 O
micro O
##gram O
##s O
des O
##og O
##est O
##rel O
( O
d O
##g O
) O
( O
15 O
tablets O
) O
( O
50 O
/ O
50 O
e O
##e O
) O
or O
40 O
micro O
##gram O
##s O
e O
##e O
+ O
25 O
micro O
##gram O
##s O
d O
##g O
( O
7 O
tablets O
) O
and O
30 O
micro O
##gram O
##s O
e O
##e O
+ O
125 O
micro O
##gram O
##s O
d O
##g O
( O
15 O
tablets O
) O
( O
40 O
/ O
30 O
e O
##e O
) O
. O
[SEP] O
[CLS] O
the O
m O
##dr O
##1 O
g O
##eno O
##type O
at O
ex O
##on O
26 O
was O
determined O
in O
114 O
healthy O
volunteers O
by O
polymer O
##ase O
chain O
reaction O
- O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
. O
[SEP] O
[CLS] O
the O
black O
circles O
represent O
the O
values O
of O
the O
individual O
patients O
. O
[SEP] O
[CLS] O
study O
highlights O
##w O
##hat O
is O
the O
current O
knowledge O
on O
the O
topic O
? O
[SEP] O
[CLS] O
re O
##tino O
##ic O
acid O
regulate O
##s O
growth O
and O
differentiation O
of O
ne O
##uro O
##blast O
##oma O
cells O
in O
v O
##it O
##ro O
, O
and O
has O
shown O
activity O
against O
human O
ne O
##uro O
##blast O
##oma O
##s O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
subjects O
who O
received O
≥ O
##7 O
doses O
of O
the O
study O
drug O
were O
considered O
e O
##val O
##ua O
##ble O
. O
[SEP] O
[CLS] O
more O
##over O
, O
excluded O
were O
patients O
with O
a O
history O
of O
p O
##el O
##vic O
ma O
##li O
##gna O
##ncy O
, O
h O
##ydro O
##ne O
##ph O
##rosis O
, O
or O
clinical O
##ly O
significant O
abnormal O
##ities O
of O
the O
upper O
u O
##rina O
##ry O
tract O
and O
those O
who O
had O
undergone O
b O
##c O
##g O
therapy O
within O
6 O
weeks O
prior O
to O
the O
start O
of O
v O
##b O
##4 O
- O
84 O
##5 O
dos O
##ing O
. O
[SEP] O
[CLS] O
these O
results O
indicated O
that O
the O
micro O
##so O
##mal O
mon O
##oo O
##xy O
##gen O
##ase O
system O
might O
be O
mainly O
responsible O
for O
the O
an O
##s O
metabolism O
. O
[SEP] O
[CLS] O
con O
##com O
##ita O
##ntly O
, O
l O
##dl O
ch O
##ole O
##ster O
##ol O
levels O
decreased O
by O
16 O
% O
. O
[SEP] O
[CLS] O
the O
median O
m O
##pa O
- O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
values O
increased O
2 O
- O
fold O
from O
32 O
. O
4 O
( O
range O
, O
13 O
. O
9 O
to O
57 O
. O
0 O
) O
mg O
x O
h O
/ O
l O
at O
3 O
weeks O
to O
65 O
. O
1 O
( O
range O
, O
32 O
. O
6 O
to O
114 O
) O
mg O
x O
h O
/ O
l O
at O
3 O
months O
after O
transplant O
##ation O
, O
whereas O
the O
median O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
values O
of O
free O
m O
##pa O
did O
not O
significantly O
change O
over O
time O
. O
[SEP] O
[CLS] O
the O
anti O
##hy O
##pert O
##ens O
##ive O
effect O
of O
oral O
##ly O
administered O
ni O
##fe O
##di O
##pine O
- O
loaded O
na O
##no O
##par O
##tic O
##les O
in O
spontaneous O
##ly O
h O
##yper O
##tensive O
rats O
. O
[SEP] O
[CLS] O
a O
two O
##fold O
reduction O
in O
g O
##i O
c O
##y O
##p O
##3 O
##a O
gave O
a O
post O
/ O
pre O
##su O
##rg O
##ical O
au B-PK
##c I-PK
ratio I-PK
of O
1 O
. O
99 O
( O
0 O
. O
83 O
– O
6 O
. O
76 O
) O
, O
whereas O
cm B-PK
##ax I-PK
increased O
to O
a O
minor O
extent O
, O
displaying O
an O
au B-PK
##c I-PK
ratio I-PK
of O
1 O
. O
80 O
( O
0 O
. O
79 O
– O
4 O
. O
00 O
) O
. O
[SEP] O
[CLS] O
( O
4 O
) O
all O
##og O
##raft O
survival O
was O
similar O
for O
r O
##34 O
##8 O
20 O
and O
40 O
mg O
/ O
kg O
, O
which O
was O
comparable O
with O
therapeutic O
##ally O
dose O
##d O
ta O
##c O
##rol O
##imus O
or O
rap O
##am O
##y O
##cin O
. O
[SEP] O
[CLS] O
patients O
with O
c O
##ea O
- O
producing O
meta O
##static O
ma O
##li O
##gna O
##ncies O
were O
administered O
a O
single O
in O
##tra O
##ven O
##ous O
dose O
of O
5 O
m O
##ci O
111 O
##in O
- O
diet O
##hyl O
##ene O
##tri O
##amine O
##pent O
##aa O
##ce O
##tic O
acid O
- O
c O
##t O
##8 O
##4 O
. O
66 O
. O
[SEP] O
[CLS] O
thus O
, O
bi O
##lia O
##ry O
ex O
##cre O
##tion O
plays O
a O
considerable O
part O
in O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
to O
##lf O
##ena O
##mic O
acid O
. O
[SEP] O
[CLS] O
further O
studies O
are O
needed O
to O
improve O
the O
reliability O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
models O
in O
est O
##imating O
serum O
dig O
##ox O
##in O
concentrations O
in O
the O
elderly O
. O
[SEP] O
[CLS] O
the O
31 O
##p O
{ O
1 O
##h O
} O
nm O
##r O
spectrum O
in O
d O
##2 O
##o O
for O
3 O
( O
δ O
= O
37 O
. O
73 O
pp O
##m O
) O
shows O
an O
additional O
##sign O
##al O
( O
δ O
= O
38 O
. O
34 O
pp O
##m O
) O
that O
may O
be O
assigned O
to O
a O
h O
##ydro O
##ly O
##zed O
##sp O
##ec O
##ies O
of O
the O
type O
[ O
( O
η O
##6 O
- O
p O
- O
c O
##yme O
##ne O
) O
r O
##u O
( O
p O
##h O
##3 O
##p O
= O
n O
- O
8 O
- O
c O
##9 O
##h O
##6 O
##n O
) O
( O
oh O
##2 O
) O
] O
2 O
+ O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
calculated O
using O
the O
log O
- O
linear O
trap O
##ez O
##oid O
##al O
rule O
, O
either O
from O
the O
time O
of O
administration O
to O
a O
specified O
time O
point O
thereafter O
, O
or O
to O
the O
last O
q O
##uant O
##ifiable O
time O
point O
( O
au B-PK
##c I-PK
##0 I-PK
- I-PK
last I-PK
) O
. O
[SEP] O
[CLS] O
ma O
##ri O
##ba O
##vir O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
the O
effects O
of O
multiple O
- O
dose O
ma O
##ri O
##ba O
##vir O
on O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
( O
c O
##y O
##p O
) O
1 O
##a O
##2 O
, O
c O
##y O
##p O
2 O
##c O
##9 O
, O
c O
##y O
##p O
2 O
##c O
##19 O
, O
c O
##y O
##p O
2d O
##6 O
, O
c O
##y O
##p O
3 O
##a O
, O
n O
- O
ace O
##ty O
##lt O
##ran O
##s O
##fer O
##ase O
- O
2 O
, O
and O
x O
##ant O
##hine O
o O
##xi O
##das O
##e O
activities O
in O
healthy O
adults O
. O
[SEP] O
[CLS] O
the O
base O
model O
was O
first O
developed O
using O
dense O
data O
. O
[SEP] O
[CLS] O
a O
ratio O
of O
ta O
##z O
to O
p O
##ip O
##c O
was O
about O
1 O
to O
4 O
in O
plasma O
levels O
. O
[SEP] O
[CLS] O
rate O
- O
limiting O
steps O
in O
oral O
absorption O
of O
a O
le O
##uc O
##ot O
##rien O
##e O
d O
##4 O
antagonist O
in O
the O
be O
##ag O
##le O
dog O
. O
[SEP] O
[CLS] O
the O
dose O
of O
t O
##rane O
##xa O
##mic O
acid O
used O
in O
our O
patient O
was O
employed O
from O
previous O
experience O
in O
trauma O
patients O
. O
[SEP] O
[CLS] O
16 O
% O
of O
the O
control O
, O
and O
in O
those O
diet O
##ary O
groups O
severe O
hem O
##or O
##r O
##hage O
##s O
in O
e O
##pid O
##idy O
##mis O
and O
other O
organs O
were O
also O
observed O
. O
[SEP] O
[CLS] O
ha O
##lop O
##eri O
##do O
##l O
and O
reduced O
ha O
##lop O
##eri O
##do O
##l O
plasma O
concentrations O
were O
ass O
##ay O
##ed O
by O
hp O
##l O
##c O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
ta O
- O
s O
##s O
##ln O
##s O
and O
ta O
- O
n O
##s O
##ln O
##s O
after O
a O
single O
dose O
in O
##tra O
##ven O
##ous O
injection O
to O
rat O
has O
been O
studied O
. O
[SEP] O
[CLS] O
the O
study O
was O
conducted O
on O
new O
z O
##eal O
##and O
white O
rabbits O
with O
three O
groups O
having O
two O
subgroup O
##s O
each O
( O
n O
= O
12 O
) O
. O
[SEP] O
[CLS] O
samples O
were O
drawn O
just O
prior O
to O
, O
and O
at O
1 O
, O
4 O
, O
and O
10 O
hours O
after O
, O
the O
observed O
dose O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
values O
( O
mean O
+ O
- O
s O
. O
d O
. O
of O
4 O
rats O
) O
for O
f O
##ad O
, O
f O
##m O
##n O
and O
r O
##f O
were O
70 O
##7 O
+ O
- O
37 O
##8 O
, O
36 O
##43 O
+ O
- O
95 O
##8 O
and O
300 O
##9 O
##5 O
+ O
- O
35 O
##44 O
nm O
##ol O
x O
min O
/ O
l O
, O
respectively O
. O
[SEP] O
[CLS] O
protection O
of O
g O
##em O
##ci O
##ta O
##bine O
with O
t O
##b O
##d O
##ms O
: O
under O
nitrogen O
, O
g O
##em O
##ci O
##ta O
##bine O
h O
##ydro O
##ch O
##lor O
##ide O
( O
6 O
, O
0 O
. O
50 O
g O
, O
1 O
. O
7 O
mm O
##ol O
) O
and O
im O
##ida O
##zo O
##le O
( O
1 O
. O
16 O
g O
, O
17 O
. O
0 O
mm O
##ol O
) O
were O
dissolved O
in O
an O
##hy O
##dr O
##ous O
dim O
##eth O
##yl O
##form O
##ami O
##de O
and O
te O
##rt O
- O
but O
##yl O
##di O
##met O
##hyl O
##si O
##ly O
##l O
chloride O
( O
t O
##b O
##d O
##ms O
- O
c O
##l O
, O
2 O
. O
65 O
g O
, O
10 O
. O
0 O
mm O
##ol O
) O
was O
added O
. O
[SEP] O
[CLS] O
insulin O
l O
##is O
##p O
##ro O
was O
provided O
in O
a O
di O
##sp O
##osa O
##ble O
pen O
for O
meal O
##time O
administration O
and O
correction O
of O
h O
##yper O
##gly O
##ca O
##emia O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
in O
the O
br O
##oms O
##ite O
##® O
bid O
group O
was O
statistical O
##ly O
significantly O
higher O
( O
p O
< O
0 O
. O
05 O
) O
than O
that O
of O
il O
##ev O
##ro O
##® O
. O
[SEP] O
[CLS] O
ch O
##roma O
##to O
##graphic O
separation O
was O
performed O
on O
a O
l O
##ich O
##ros O
##pher O
c O
##n O
column O
with O
a O
mobile O
phase O
of O
met O
##han O
##ol O
and O
water O
( O
containing O
0 O
. O
1 O
% O
form O
##ic O
acid O
) O
( O
70 O
: O
30 O
, O
v O
/ O
v O
) O
. O
[SEP] O
[CLS] O
valid O
##ated O
high O
performance O
liquid O
ch O
##roma O
##tography O
- O
u O
##v O
detection O
method O
for O
the O
determination O
of O
da O
##pt O
##omy O
##cin O
in O
human O
plasma O
. O
[SEP] O
[CLS] O
for O
in O
v O
##it O
##ro O
experiments O
, O
extract O
from O
mouse O
ma O
##mma O
##ry O
t O
##umour O
##s O
were O
prepared O
and O
in O
##cu O
##bate O
##d O
with O
radio O
##io O
##dina O
##ted O
p O
##14 O
##9 O
- O
q O
##y O
p O
##eptide O
in O
the O
presence O
of O
a O
cross O
- O
linking O
re O
##age O
##nt O
. O
[SEP] O
[CLS] O
forty O
patients O
with O
active O
p O
##ept O
##ic O
ul O
##cer O
were O
randomly O
assigned O
to O
receive O
a O
single O
oral O
dose O
of O
r O
##abe O
##pra O
##zo O
##le O
10 O
mg O
, O
o O
##me O
##pra O
##zo O
##le O
20 O
mg O
, O
or O
pan O
##top O
##raz O
##ole O
40 O
mg O
; O
the O
in O
##tra O
##gas O
##tric O
p O
##h O
was O
monitored O
1 O
hour O
before O
and O
24 O
hours O
after O
the O
dose O
was O
given O
. O
[SEP] O
[CLS] O
assessment O
of O
re O
##nal O
function O
by O
means O
of O
plasma B-PK
clearance I-PK
of O
a O
suitable O
marker O
has O
become O
standard O
procedure O
for O
est O
##imation O
of O
g O
##lo O
##mer O
##ular O
fi O
##ltration O
rate O
( O
g O
##f O
##r O
) O
. O
[SEP] O
[CLS] O
within O
each O
organ O
compartment O
, O
there O
are O
three O
sub O
- O
compartment O
##s O
representing O
cap O
##illa O
##ry O
blood O
, O
tissue O
, O
and O
p O
##ha O
##go O
##cy O
##ti O
##zing O
cells O
( O
p O
##cs O
) O
. O
[SEP] O
[CLS] O
no O
changes O
in O
electro O
##card O
##io O
##gram O
or O
vital O
signs O
were O
observed O
. O
[SEP] O
[CLS] O
the O
student O
’ O
s O
t O
test O
was O
used O
to O
compare O
in O
##f O
##lix O
##ima O
##b O
concentrations O
, O
h O
##s O
- O
c O
##rp O
and O
f O
##c O
levels O
in O
study O
subjects O
and O
controls O
with O
the O
significance O
level O
set O
at O
5 O
% O
. O
[SEP] O
[CLS] O
the O
lo O
##q O
was O
also O
the O
lowest O
point O
of O
the O
ca O
##li O
##bra O
##tion O
curve O
and O
was O
set O
at O
200 O
ng O
· O
m O
##l O
##− O
##1 O
( O
n O
= O
6 O
, O
mean O
result O
: O
190 O
. O
2 O
± O
3 O
. O
44 O
ng O
· O
m O
##l O
##− O
##1 O
) O
. O
[SEP] O
[CLS] O
this O
study O
was O
approved O
by O
the O
animal O
et O
##hic O
committee O
of O
university O
of O
ad O
##nan O
men O
##der O
##es O
. O
[SEP] O
[CLS] O
however O
, O
600 O
mg O
e O
##f O
##v O
has O
been O
associated O
with O
ne O
##uro O
##to O
##xi O
##city O
( O
r O
##ak O
##hman O
##ina O
and O
van O
den O
an O
##ker O
, O
2010 O
; O
a O
##post O
##olo O
##va O
et O
al O
. O
, O
2015 O
) O
. O
[SEP] O
[CLS] O
as O
shown O
in O
table O
2 O
, O
peak B-PK
concentration I-PK
was O
found O
to O
be O
significantly O
higher O
for O
d O
- O
p O
##n O
##ps O
( O
1 O
. O
92 O
± O
0 O
. O
69 O
μ O
##g O
/ O
m O
##l O
) O
and O
d O
- O
c O
##n O
##ps O
( O
2 O
. O
44 O
± O
0 O
. O
74 O
μ O
##g O
/ O
m O
##l O
) O
than O
for O
da O
##id O
##ze O
##in O
suspension O
group O
( O
1 O
. O
35 O
± O
0 O
. O
47 O
μ O
##g O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
m O
##cc O
##s O
( O
c O
##eo O
##lus O
r O
##c O
- O
a O
##5 O
##9 O
##1 O
n O
##f O
; O
as O
##ahi O
ka O
##sei O
, O
to O
##ky O
##o O
, O
j O
##apa O
##n O
) O
was O
commercially O
obtained O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##dynamic O
assessment O
confirmed O
par O
##p O
in O
##hibition O
although O
no O
dose O
response O
was O
apparent O
. O
[SEP] O
[CLS] O
be O
##rber O
##ine O
( O
be O
##r O
) O
, O
possessing O
a O
variety O
of O
p O
##har O
##ma O
##cological O
functions O
, O
has O
caused O
a O
growing O
interest O
in O
recent O
years O
. O
[SEP] O
[CLS] O
the O
drug O
is O
highly O
( O
greater O
than O
99 O
% O
) O
bound O
to O
plasma O
album O
##ins O
and O
penetrate O
##s O
easily O
into O
the O
s O
##yn O
##ov O
##ial O
fluid O
. O
[SEP] O
[CLS] O
m O
##dh O
##p O
was O
found O
to O
be O
the O
major O
u O
##rina O
##ry O
meta O
##bol O
##ite O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
such O
as O
half B-PK
‐ I-PK
life I-PK
and O
clearance B-PK
, O
were O
then O
calculated O
using O
non O
‐ O
compartment O
##al O
analysis O
of O
the O
data O
from O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
. O
[SEP] O
[CLS] O
compared O
with O
the O
reference O
treatment O
, O
the O
au B-PK
##cs I-PK
( I-PK
0 I-PK
– I-PK
∞ I-PK
) I-PK
for O
do O
##lut O
##eg O
##ra O
##vir O
after O
a O
##ba O
##ca O
##vir O
/ O
do O
##lut O
##eg O
##ra O
##vir O
/ O
la O
##mi O
##vu O
##dine O
– O
high O
mineral O
— O
immediate O
, O
a O
##ba O
##ca O
##vir O
/ O
do O
##lut O
##eg O
##ra O
##vir O
/ O
la O
##mi O
##vu O
##dine O
– O
high O
mineral O
— O
delayed O
, O
a O
##ba O
##ca O
##vir O
/ O
do O
##lut O
##eg O
##ra O
##vir O
/ O
la O
##mi O
##vu O
##dine O
– O
zero O
mineral O
— O
immediate O
, O
and O
a O
##ba O
##ca O
##vir O
/ O
do O
##lut O
##eg O
##ra O
##vir O
/ O
la O
##mi O
##vu O
##dine O
– O
zero O
mineral O
— O
delayed O
were O
56 O
% O
, O
53 O
% O
, O
58 O
% O
, O
and O
54 O
% O
higher O
, O
respectively O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
is O
##onia O
##zi O
##d O
p O
##har O
##ma O
##co O
##kin O
##etics O
were O
best O
explained O
by O
a O
2 O
- O
compartment O
model O
, O
whereas O
r O
##if O
##amp O
##in O
and O
p O
##yra O
##zin O
##ami O
##de O
concentrations O
were O
best O
explained O
by O
a O
1 O
- O
compartment O
model O
. O
[SEP] O
[CLS] O
extraction O
recover O
##ies O
ranged O
from O
64 O
% O
to O
115 O
% O
, O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
matrix O
effects O
were O
≤ O
##21 O
% O
, O
and O
overall O
process O
efficiency O
ranged O
from O
57 O
% O
to O
93 O
% O
at O
low O
and O
high O
quality O
control O
concentrations O
. O
[SEP] O
[CLS] O
of O
the O
cocaine O
groups O
, O
18 O
of O
23 O
e O
##ac O
##d O
subjects O
and O
3 O
of O
7 O
d O
##ff O
##c O
##d O
subjects O
were O
cigarette O
smoke O
##rs O
. O
[SEP] O
[CLS] O
the O
rats O
were O
then O
switched O
to O
the O
iron O
- O
def O
##icient O
diet O
( O
ain O
- O
93 O
##g O
pu O
##rified O
rode O
##nt O
diet O
; O
dye O
##ts O
in O
##c O
. O
, O
bet O
##hl O
##eh O
##em O
, O
p O
##a O
, O
u O
. O
s O
. O
a O
. O
) O
which O
was O
administered O
to O
all O
animals O
from O
day O
0 O
to O
day O
24 O
of O
the O
study O
( O
for O
the O
complete O
diet O
composition O
see O
table O
s O
##1 O
) O
. O
[SEP] O
[CLS] O
is O
##onia O
##zi O
##d O
in O
##hibit O
##ed O
the O
clearance B-PK
of O
ch O
##lor O
##zo O
##xa O
##zone O
by O
58 O
% O
, O
as O
assessed O
from O
plasma O
data O
, O
and O
in O
##hibit O
##ed O
the O
formation O
of O
ace O
##tam O
##ino O
##phe O
##n O
th O
##io O
##eth O
##er O
meta O
##bol O
##ites O
( O
a O
measure O
of O
the O
formation O
of O
the O
he O
##pa O
##to O
##to O
##xin O
n O
- O
ace O
##ty O
##l O
- O
p O
- O
ben O
##zo O
##quin O
##one O
im O
##ine O
and O
cat O
##ech O
##ol O
o O
##xi O
##da O
##tive O
meta O
##bol O
##ites O
of O
ace O
##tam O
##ino O
##phe O
##n O
, O
as O
determined O
from O
their O
recovery O
in O
urine O
, O
by O
63 O
% O
and O
49 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
both O
d O
##tic O
and O
a O
##ic O
have O
re O
##p O
##rod O
##uc O
##ible O
retention O
times O
on O
the O
amid O
##e O
- O
80 O
hp O
##l O
##c O
column O
. O
[SEP] O
[CLS] O
after O
an O
oral O
administration O
of O
be O
##rga O
##pt O
##en O
at O
a O
dose O
of O
15 O
mg O
kg O
##− O
##1 O
to O
the O
rats O
, O
be O
##rga O
##pt O
##en O
could O
be O
detected O
in O
rat O
urine O
until O
72 O
h O
. O
be O
##rga O
##pt O
##en O
increased O
rapidly O
in O
urine O
during O
a O
time O
period O
of O
4 O
– O
8 O
h O
. O
after O
8 O
h O
however O
, O
there O
was O
a O
gradual O
increase O
of O
be O
##rga O
##pt O
##en O
in O
urine O
. O
[SEP] O
[CLS] O
the O
efficacy O
of O
most O
anti O
##can O
##cer O
drugs O
is O
highly O
limited O
in O
v O
##ivo O
due O
mainly O
to O
poor O
p O
##har O
##ma O
##co O
##kin O
##etics O
behavior O
including O
poor O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
after O
extra O
##vas O
##cular O
administration O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
el O
##trom O
##bo O
##pa O
##g O
were O
dose O
dependent O
and O
linear O
, O
and O
el O
##trom O
##bo O
##pa O
##g O
increased O
plate O
##let O
counts O
in O
a O
dose O
- O
dependent O
manner O
. O
[SEP] O
[CLS] O
these O
valid O
##ation O
data O
indicated O
that O
the O
present O
l O
##c O
- O
m O
##s O
method O
, O
including O
the O
pre O
##tre O
##at O
##ment O
procedure O
, O
was O
sufficient O
for O
the O
determination O
of O
plasma O
m O
##p O
##c O
concentration O
. O
[SEP] O
[CLS] O
comparison O
of O
meta O
##bol O
##ite O
recover O
##ies O
in O
urine O
indicated O
a O
positive O
correlation O
between O
activation O
and O
in O
##act O
##ivation O
routes O
of O
metabolism O
. O
[SEP] O
[CLS] O
alternate O
anti O
##biotics O
may O
be O
equally O
effective O
and O
allow O
similar O
dos O
##ing O
in O
the O
chronic O
hem O
##od O
##ial O
##ys O
##is O
population O
. O
[SEP] O
[CLS] O
these O
results O
indicate O
that O
differences O
in O
these O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
do O
not O
account O
for O
the O
well O
- O
established O
clinical O
observation O
that O
some O
patients O
require O
daily O
pre O
##dn O
##ison O
##e O
doses O
and O
that O
their O
disease O
cannot O
be O
managed O
with O
alternate O
- O
day O
s O
##tero O
##id O
therapy O
. O
[SEP] O
[CLS] O
shifts O
of O
d O
##lm O
##o O
, O
so O
, O
and O
so O
##l O
in O
the O
three O
groups O
with O
me O
##lat O
##oni O
##n O
were O
plot O
##ted O
as O
function O
of O
clock O
to O
##a O
( O
fi O
##g O
. O
3 O
##a O
) O
and O
as O
function O
of O
circa O
##dian O
to O
##a O
( O
fi O
##g O
. O
3 O
##b O
) O
. O
[SEP] O
[CLS] O
the O
cumulative O
percentage O
of O
pro O
##ges O
##tero O
##ne O
released O
from O
the O
na O
##no O
##par O
##tic O
##les O
formed O
by O
the O
addition O
of O
20 O
% O
, O
10 O
% O
, O
and O
5 O
% O
of O
s O
##te O
##ari O
##c O
acid O
at O
the O
end O
of O
10 O
h O
was O
88 O
± O
5 O
. O
4 O
, O
76 O
± O
8 O
. O
2 O
, O
and O
60 O
% O
± O
5 O
. O
3 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
antibodies O
( O
14 O
##c O
##10 O
h O
##g O
##1 O
and O
d O
##29 O
h O
##g O
##1 O
) O
were O
used O
at O
a O
fixed O
concentration O
of O
6 O
##μ O
##g O
/ O
m O
##l O
and O
pre O
- O
in O
##cu O
##bate O
##d O
with O
e O
##1 O
f O
##ab O
or O
anti O
- O
den O
##v O
- O
2 O
f O
##ab O
for O
one O
hour O
at O
room O
temperature O
, O
at O
a O
starting O
concentration O
of O
50 O
##μ O
##g O
/ O
m O
##l O
and O
serial O
##ly O
di O
##lut O
##ed O
by O
half O
a O
log O
in O
blocking O
buffer O
( O
4 O
% O
m O
##p O
##bs O
) O
, O
at O
room O
temperature O
, O
before O
the O
addition O
to O
den O
##v O
- O
1 O
. O
[SEP] O
[CLS] O
considering O
there O
are O
many O
components O
of O
originated O
from O
r O
##hi O
##zo O
##ma O
z O
##ing O
##iber O
##is O
re O
##cens O
, O
the O
probable O
reason O
was O
that O
the O
main O
components O
of O
r O
##hi O
##zo O
##ma O
z O
##ing O
##iber O
##is O
re O
##cens O
were O
hard O
to O
meta O
##bol O
##ize O
. O
[SEP] O
[CLS] O
these O
results O
describe O
an O
effective O
strategy O
for O
oral O
delivery O
of O
da O
##id O
##ze O
##in O
- O
loaded O
p O
##l O
##ga O
na O
##no O
##par O
##tic O
##les O
and O
might O
provide O
a O
fresh O
approach O
to O
enhancing O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
drugs O
with O
poor O
lip O
##op O
##hil O
##ic O
and O
poor O
h O
##ydro O
##phi O
##lic O
properties O
. O
[SEP] O
[CLS] O
further O
##more O
, O
no O
information O
is O
available O
defining O
the O
relationship O
between O
drug O
exposure O
and O
clinical O
response O
. O
[SEP] O
[CLS] O
these O
results O
suggest O
that O
no O
s O
##ynth O
##ase O
in O
##hibition O
by O
l O
- O
name O
enhance O
##s O
the O
cardiac O
toxicity O
of O
b O
##up O
##iva O
##ca O
##ine O
, O
probably O
by O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
action O
, O
and O
reduces O
its O
central O
nervous O
system O
toxicity O
, O
probably O
by O
a O
p O
##har O
##ma O
##co O
##dynamic O
action O
. O
[SEP] O
[CLS] O
to O
determine O
the O
milk B-PK
- I-PK
to I-PK
- I-PK
plasma I-PK
( I-PK
m I-PK
/ I-PK
p I-PK
) I-PK
concentration I-PK
ratio I-PK
of O
c O
##ele O
##co O
##xi O
##b O
, O
and O
estimate O
likely O
infant O
exposure O
. O
[SEP] O
[CLS] O
the O
plasma O
concentrations O
were O
expressed O
as O
arithmetic O
mean O
± O
standard O
de O
##viation O
( O
s O
##d O
) O
. O
[SEP] O
[CLS] O
in O
the O
group O
, O
peak B-PK
serum I-PK
concentration I-PK
of O
mm O
##c O
was O
0 O
. O
29 O
micro O
##gram O
##s O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
the O
long O
- O
chain O
h O
##ydro O
##phobic O
m O
##oi O
##ety O
of O
surf O
##act O
##ants O
showed O
a O
greater O
stab O
##ilization O
effect O
than O
polo O
##xa O
##mers O
and O
gel O
##uc O
##ires O
. O
[SEP] O
[CLS] O
the O
objective O
of O
the O
study O
was O
to O
prepare O
and O
evaluate O
a O
18 O
##f O
- O
radio O
##la O
##bled O
trace O
##r O
( O
al O
##18 O
##f O
- O
5 O
) O
, O
der O
##ivated O
from O
the O
anti O
##tum O
##or O
agent O
2 O
- O
( O
4 O
- O
amino O
##phe O
##ny O
##l O
) O
ben O
##zo O
##thi O
##az O
##ole O
, O
as O
a O
pet O
probe O
for O
tumor O
imaging O
. O
[SEP] O
[CLS] O
the O
influence O
of O
different O
dos O
##ing O
intervals O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
changes O
in O
bone O
turnover O
markers O
, O
and O
safety O
profiles O
of O
twice O
‐ O
weekly O
28 O
. O
2 O
‐ O
μ O
##g O
te O
##rip O
##ara O
##tide O
injection O
##s O
over O
6 O
weeks O
. O
[SEP] O
[CLS] O
the O
apparent B-PK
clearance I-PK
was O
1 O
. O
46 O
+ O
- O
0 O
. O
45 O
l O
/ O
h O
##r O
with O
an O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
in I-PK
the I-PK
terminal I-PK
phase I-PK
of O
40 O
##7 O
+ O
- O
111 O
l O
( O
data O
for O
both O
s O
##ten O
##t O
doses O
pool O
##ed O
) O
. O
[SEP] O
[CLS] O
in O
order O
to O
c O
##lar O
##ify O
whether O
re O
##pi O
##rina O
##st O
, O
an O
inhibitor O
of O
chemical O
media O
##tor O
release O
, O
could O
influence O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
##op O
##hyl O
##line O
, O
a O
loading O
test O
using O
in O
##tra O
##ven O
##ous O
injection O
of O
amino O
##phy O
##llin O
##e O
was O
performed O
in O
10 O
subjects O
with O
br O
##on O
##chia O
##l O
as O
##th O
##ma O
before O
and O
after O
treatment O
with O
300 O
mg O
/ O
day O
of O
re O
##pi O
##rina O
##st O
. O
[SEP] O
[CLS] O
su O
##l O
##pha O
##met O
##ho O
##xa O
##zo O
##le O
, O
su O
##l O
##pha O
##di O
##met O
##hyl O
##ox O
##az O
##ole O
and O
su O
##l O
##pha O
##di O
##met O
##ho O
##xin O
##e O
were O
once O
administered O
in O
goats O
via O
oral O
and O
i O
. O
v O
. O
route O
( O
100 O
mg O
/ O
kg O
b O
. O
w O
##t O
. O
) O
for O
determination O
of O
plasma O
and O
urine O
concentrations O
of O
the O
unchanged O
su O
##l O
##phon O
##ami O
##des O
and O
their O
ace O
##ty O
##lated O
derivatives O
, O
kinetic O
behavior O
, O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
tissue O
levels O
and O
ace O
##ty O
##lation O
. O
[SEP] O
[CLS] O
other O
exclusion O
criteria O
included O
known O
brain O
or O
le O
##pt O
##ome O
##ning O
##eal O
meta O
##sta O
##ses O
, O
no O
prior O
e O
##g O
##f O
##r O
inhibitor O
therapy O
, O
no O
known O
ne O
##uro O
##mus O
##cular O
disorders O
as O
well O
as O
known O
h O
##yper O
##sen O
##si O
##ti O
##vity O
or O
all O
##er O
##gy O
to O
h O
##m O
##g O
- O
co O
##a O
red O
##uc O
##tase O
inhibitor O
##s O
including O
r O
##os O
##u O
##vas O
##tat O
##in O
in O
as O
##ian O
populations O
which O
were O
also O
excluded O
[ O
33 O
] O
, O
( O
us O
f O
##da O
public O
health O
advisory O
, O
2 O
march O
2005 O
, O
www O
. O
f O
##da O
. O
go O
##v O
) O
. O
[SEP] O
[CLS] O
bench O
top O
stability O
was O
assessed O
by O
using O
six O
replica O
##tes O
of O
l O
##q O
##c O
and O
h O
##q O
##c O
stored O
at O
room O
temperature O
for O
18 O
h O
. O
[SEP] O
[CLS] O
the O
effect O
of O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
on O
study O
power O
was O
assessed O
by O
first O
setting O
the O
coefficient O
of O
variation O
( O
c O
##v O
) O
of O
o O
##at O
##p O
##1 O
##b O
##1 O
and O
o O
##at O
##p O
##1 O
##b O
##3 O
abundance O
to O
0 O
and O
carrying O
out O
the O
same O
power O
analysis O
as O
above O
. O
[SEP] O
[CLS] O
these O
results O
indicate O
that O
protein O
binding O
can O
be O
successfully O
included O
in O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
. O
[SEP] O
[CLS] O
the O
se O
##ma O
##g O
##lut O
##ide O
plasma O
concentrations O
were O
measured O
following O
protein O
precipitation O
using O
a O
valid O
##ated O
liquid O
ch O
##roma O
##tography O
ass O
##ay O
followed O
by O
a O
tandem O
mass O
s O
##pect O
##rome O
##try O
ass O
##ay O
( O
c O
##ele O
##rion O
in O
##c O
. O
f O
##eh O
##ral O
##tor O
##f O
, O
s O
##witz O
##erland O
) O
; O
see O
[ O
24 O
] O
for O
more O
details O
. O
[SEP] O
[CLS] O
using O
commercial O
g O
##erman O
capsule O
##s O
as O
the O
reference O
( O
r O
) O
, O
two O
coating O
formulation O
##s O
were O
selected O
for O
tests O
after O
optimization O
: O
p O
##h O
- O
dependent O
p O
##elle O
##ts O
with O
a O
ratio O
of O
e O
##ud O
##rag O
##it O
( O
® O
) O
ne O
##30 O
##d O
/ O
l O
##30 O
##d O
##55 O
of O
10 O
: O
1 O
, O
a O
3 O
% O
coating O
level O
( O
t O
( O
1 O
) O
) O
, O
and O
p O
##h O
- O
independent O
p O
##elle O
##ts O
with O
a O
e O
##ud O
##rag O
##it O
( O
® O
) O
ne O
##30 O
##d O
coating O
level O
( O
t O
( O
2 O
) O
) O
of O
3 O
. O
5 O
% O
. O
[SEP] O
[CLS] O
the O
ll O
##o O
##q O
was O
expressed O
for O
the O
anal O
##yte O
concentration O
having O
response O
at O
least O
5 O
times O
more O
compared O
to O
blank O
response O
. O
[SEP] O
[CLS] O
subsequently O
, O
t O
##f O
##v O
undergo O
##es O
two O
p O
##hos O
##ph O
##ory O
##lation O
steps O
forming O
ten O
##of O
##ov O
##ir O
dip O
##hos O
##phate O
( O
t O
##f O
##v O
- O
d O
##p O
) O
, O
which O
is O
an O
analog O
of O
end O
##ogen O
##ous O
de O
##ox O
##ya O
##den O
##os O
##ine O
trip O
##hos O
##phate O
. O
[SEP] O
[CLS] O
no O
single O
sat O
##urable O
elimination O
pathway O
was O
identified O
. O
[SEP] O
[CLS] O
at O
the O
1400 O
mg O
bid O
dose O
level O
, O
in O
an O
expanded O
co O
##hor O
##t O
during O
dose O
de O
- O
es O
##cal O
##ation O
one O
patient O
experienced O
a O
grade O
4 O
h O
##y O
##pot O
##ens O
##ion O
and O
a O
rising O
grade O
2 O
c O
##rea O
##tin O
##ine O
that O
were O
dose O
limiting O
, O
and O
a O
second O
patient O
had O
a O
rising O
grade O
2 O
c O
##rea O
##tin O
##ine O
in O
cycle O
1 O
, O
where O
treatment O
was O
terminated O
before O
it O
reached O
a O
grade O
3 O
and O
was O
therefore O
considered O
dose O
limiting O
. O
[SEP] O
[CLS] O
based O
on O
coefficient O
of O
drug O
interaction O
( O
c O
##di O
) O
values O
, O
the O
combination O
of O
try O
##ps O
##ino O
##gen O
plus O
ch O
##ym O
##ot O
##ry O
##ps O
##ino O
##gen O
a O
demonstrated O
greater O
growth O
in O
##hibition O
at O
ratios O
of O
1 O
: O
4 O
, O
1 O
: O
6 O
and O
1 O
: O
8 O
compared O
to O
the O
1 O
: O
1 O
ratio O
in O
all O
cell O
lines O
tested O
except O
for O
78 O
##6 O
- O
o O
, O
g O
- O
36 O
##1 O
, O
b O
##t O
- O
47 O
##4 O
and O
h O
##l O
- O
60 O
t O
##umour O
cells O
( O
fi O
##g O
. O
1 O
; O
supplement O
##ary O
table O
s O
##4 O
) O
. O
[SEP] O
[CLS] O
in O
study O
1 O
, O
44 O
subjects O
were O
random O
##ized O
and O
included O
in O
the O
“ O
all O
subjects O
” O
population O
: O
93 O
% O
( O
n O
= O
41 O
) O
completed O
the O
study O
and O
received O
all O
planned O
treatments O
; O
three O
subjects O
discontinued O
study O
medication O
due O
to O
an O
sa O
##e O
( O
n O
= O
1 O
) O
or O
investigator O
discretion O
( O
n O
= O
2 O
) O
. O
[SEP] O
[CLS] O
the O
fully O
human O
anti O
- O
lip O
##op O
##oly O
##sa O
##cc O
##hari O
##de O
( O
l O
##ps O
) O
im O
##mu O
##no O
##g O
##lo O
##bul O
##in O
m O
( O
i O
##g O
##m O
) O
mon O
##oc O
##lon O
##al O
anti O
##body O
pan O
##ob O
##ac O
##uma O
##b O
was O
developed O
as O
an O
ad O
##junct O
##ive O
im O
##mu O
##not O
##her O
##ap O
##y O
for O
the O
treatment O
of O
o O
##11 O
se O
##rot O
##ype O
pseudo O
##mona O
##s O
a O
##er O
##ug O
##ino O
##sa O
infections O
. O
[SEP] O
[CLS] O
h O
##ts O
advancement O
##sha O
##ve O
accelerated O
the O
preparation O
of O
drug O
##like O
molecules O
. O
24 O
, O
25 O
comparatively O
, O
examples O
of O
creating O
larger O
, O
well O
- O
defined O
systems O
##using O
high O
- O
through O
##put O
machinery O
are O
emerging O
, O
such O
as O
un O
##imo O
##le O
##cular O
##ma O
##c O
##rom O
##ole O
##cule O
##s O
##26 O
and O
re O
##versible O
addition O
– O
fragment O
##ation O
##cha O
##in O
transfer O
( O
r O
##aft O
) O
polymer O
##s O
. O
27 O
we O
conducted O
##raft O
chemistry O
on O
a O
lab O
scale O
first O
( O
figure O
s O
- O
1 O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
of O
bi O
##lia O
##ry O
ex O
##cre O
##tion O
. O
[SEP] O
[CLS] O
the O
following O
settings O
were O
used O
: O
ion O
spray O
voltage O
350 O
##0 O
v O
, O
collision O
energy O
10 O
e O
##v O
, O
vapor O
##izer O
temperature O
300 O
° O
##c O
, O
tube O
lens O
voltage O
at O
60 O
v O
, O
sheath O
and O
auxiliary O
gas O
pressure O
40 O
and O
35 O
ps O
##i O
, O
respectively O
. O
[SEP] O
[CLS] O
during O
in O
##fusion O
of O
s O
##t O
##gs O
the O
medium O
- O
chain O
fatty O
acids O
o O
##ct O
##ano O
##ic O
( O
c O
: O
8 O
) O
and O
de O
##cano O
##ic O
acid O
( O
c O
: O
10 O
) O
constituted O
approximately O
half O
of O
circulating O
fatty O
acids O
that O
correspond O
to O
the O
composition O
##al O
ratio O
of O
the O
em O
##ul O
##sion O
. O
[SEP] O
[CLS] O
figure O
2 O
shows O
the O
percentage O
of O
mit O
##omy O
##cin O
c O
absorbed O
from O
the O
per O
##ito O
##nea O
##l O
space O
as O
compared O
to O
the O
p O
##le O
##ural O
space O
. O
[SEP] O
[CLS] O
the O
median O
v O
##agi O
##nal O
p O
##h O
prior O
to O
i O
##v O
##r O
placement O
( O
visits O
0 O
and O
1 O
) O
was O
4 O
. O
0 O
( O
i O
##q O
##r O
, O
4 O
. O
0 O
– O
4 O
. O
5 O
) O
, O
and O
with O
the O
t O
##d O
##f O
and O
t O
##d O
##f O
- O
ft O
##c O
pod O
- O
i O
##v O
##rs O
in O
place O
was O
4 O
. O
5 O
( O
i O
##q O
##r O
, O
4 O
. O
1 O
– O
4 O
. O
5 O
) O
and O
4 O
. O
0 O
( O
i O
##q O
##r O
, O
4 O
. O
0 O
– O
4 O
. O
5 O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
mi I-PK
##c I-PK
ratio I-PK
was O
calculated O
by O
dividing O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
by O
mi O
##cs O
0 O
. O
5 O
, O
1 O
and O
2 O
mg O
/ O
l O
. O
[SEP] O
[CLS] O
in O
v O
##it O
##ro O
release O
studies O
at O
p O
##h O
6 O
. O
8 O
phosphate O
buffer O
( O
p O
##bs O
) O
and O
at O
p O
##h O
1 O
. O
2 O
h O
##c O
##l O
0 O
. O
1 O
##n O
showed O
a O
slow O
release O
in O
both O
media O
. O
[SEP] O
[CLS] O
steady O
- O
state O
plasma O
v O
##pa O
concentration O
- O
time O
profiles O
from O
5 O
published O
di O
##val O
##p O
##ro O
##ex O
- O
er O
studies O
( O
healthy O
subjects O
and O
e O
##pile O
##psy O
patients O
) O
were O
analyzed O
. O
[SEP] O
[CLS] O
the O
label O
##ing O
yield O
, O
in O
v O
##it O
##ro O
stability O
and O
in O
v O
##ivo O
bio O
##dis O
##tribution O
profile O
of O
( O
90 O
) O
y O
- O
m O
##n O
##ps O
were O
compared O
. O
[SEP] O
[CLS] O
the O
flow O
rate O
was O
set O
at O
500 O
µ O
##l O
/ O
min O
and O
the O
temperature O
of O
the O
column O
was O
maintained O
at O
40 O
° O
##c O
. O
[SEP] O
[CLS] O
p O
##osa O
##cona O
##zo O
##le O
is O
a O
lip O
##op O
##hil O
##ic O
t O
##ria O
##zo O
##le O
anti O
##fu O
##nga O
##l O
that O
exhibits O
variable O
absorption O
when O
administered O
oral O
##ly O
. O
[SEP] O
[CLS] O
the O
c O
##y O
##c O
##lin O
- O
dependent O
kinase O
inhibitor O
u O
##c O
##n O
- O
01 O
plus O
c O
##is O
##p O
##lat O
##in O
in O
advanced O
solid O
tumors O
: O
a O
ca O
##li O
##fo O
##rn O
##ia O
cancer O
consortium O
phase O
i O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
molecular O
co O
##rrel O
##ative O
trial O
. O
[SEP] O
[CLS] O
however O
, O
no O
association O
was O
observed O
. O
[SEP] O
[CLS] O
the O
mobile O
phase O
was O
prepared O
by O
mixing O
met O
##han O
##ol O
, O
ace O
##ton O
##it O
##ril O
##e O
and O
10 O
mm O
am O
##mon O
##ium O
ace O
##tate O
buffer O
( O
p O
##h O
4 O
. O
0 O
) O
( O
filtered O
through O
0 O
. O
22 O
μ O
##m O
mill O
##ip O
##ore O
filter O
) O
( O
29 O
: O
1 O
: O
70 O
, O
v O
/ O
v O
/ O
v O
) O
. O
[SEP] O
[CLS] O
this O
increased O
up O
##take O
could O
be O
attributed O
to O
the O
re O
##tic O
##ulo O
##end O
##oth O
##eli O
##al O
system O
leading O
to O
an O
increase O
in O
re O
##s O
##ver O
##at O
##rol O
concentration O
in O
the O
liver O
. O
[SEP] O
[CLS] O
the O
results O
properly O
indicated O
that O
moderate O
clearance B-PK
and O
high O
extra O
##vas O
##cular O
distribution O
would O
be O
exhibited O
by O
1 O
d O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
the O
findings O
indicate O
that O
the O
weight O
for O
age O
are O
not O
con O
##cor O
##dant O
for O
the O
two O
middle O
weight O
groups O
( O
15 O
- O
25 O
kg O
and O
> O
25 O
- O
35 O
kg O
) O
. O
[SEP] O
[CLS] O
after O
dose O
normal O
##ization O
the O
mean O
peak B-PK
plasma I-PK
concentration I-PK
was O
0 O
. O
68 O
micro O
##m O
( O
range O
0 O
. O
12 O
- O
1 O
. O
38 O
) O
and O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
1 O
. O
37 O
micro O
##m O
. O
h O
( O
range O
0 O
. O
12 O
- O
3 O
. O
04 O
) O
. O
[SEP] O
[CLS] O
this O
equal O
##ed O
an O
estimated O
##b O
##lo O
##od O
concentration O
of O
3 O
. O
08 O
× O
101 O
, O
3 O
. O
08 O
× O
10 O
– O
1 O
, O
3 O
. O
08 O
× O
10 O
– O
3 O
, O
and O
3 O
. O
08 O
× O
##10 O
– O
4 O
ng O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
sub O
##ling O
##ual O
administration O
of O
de O
##tom O
##id O
##ine O
or O
##om O
##uc O
##osa O
##l O
gel O
at O
40 O
μ O
##g O
/ O
kg O
produces O
safe O
se O
##dation O
in O
horses O
. O
[SEP] O
[CLS] O
in O
the O
present O
study O
, O
the O
au B-PK
##ct I-PK
##au I-PK
and O
cm B-PK
##ax I-PK
were O
11 O
, O
69 O
##0 O
. O
71 O
hour O
• O
ng O
/ O
m O
##l O
and O
76 O
##4 O
. O
3 O
ng O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
when O
combined O
with O
p O
##az O
##op O
##ani O
##b O
, O
800 O
mg O
daily O
, O
the O
recommended O
doses O
for O
oral O
top O
##ote O
##can O
are O
: O
8 O
mg O
weekly O
and O
2 O
. O
5 O
mg O
daily O
- O
times O
- O
five O
. O
[SEP] O
[CLS] O
all O
regulated O
procedures O
on O
living O
animals O
were O
carried O
out O
under O
##the O
authority O
of O
a O
license O
issued O
by O
the O
home O
office O
under O
the O
animals O
( O
scientific O
procedures O
) O
[SEP] O
[CLS] O
o O
##xy O
##te O
##tra O
##cy O
##cline O
chloride O
analytical O
standard O
( O
97 O
% O
purity O
) O
and O
do O
##xy O
##cy O
##cline O
( O
internal O
standard O
, O
is O
) O
were O
supplied O
by O
si O
##gma O
al O
##dric O
##h O
, O
m O
##o O
( O
us O
##a O
) O
. O
[SEP] O
[CLS] O
in O
rescue O
experiments O
, O
an O
##ae O
##st O
##he O
##tized O
rats O
were O
injected O
s O
. O
c O
. O
with O
multiple O
m O
##ld O
of O
venom O
and O
in O
##fused O
i O
. O
v O
. O
with O
drugs O
commonly O
used O
in O
the O
treatment O
of O
s O
##cor O
##pion O
en O
##ven O
##oma O
##tion O
. O
[SEP] O
[CLS] O
the O
any O
- O
hit O
model O
was O
consistent O
with O
poor O
##er O
survival O
, O
but O
was O
not O
statistical O
##ly O
significant O
. O
[SEP] O
[CLS] O
the O
concentrations O
of O
transfer O
##rin O
and O
album O
##in O
were O
determined O
by O
ne O
##phe O
##lo O
##metry O
. O
[SEP] O
[CLS] O
[ O
14 O
##c O
] O
5 O
- O
f O
##u O
was O
purchased O
from O
m O
##ora O
##ve O
##k O
bio O
##chemical O
##s O
( O
br O
##ea O
, O
ca O
##li O
##fo O
##rn O
##ia O
, O
us O
) O
. O
[SEP] O
[CLS] O
the O
potential O
of O
the O
glass O
##y O
carbon O
working O
electro O
##de O
was O
set O
at O
+ O
800 O
m O
##v O
. O
the O
limit O
of O
q O
##uant O
##itation O
was O
12 O
. O
5 O
ng O
m O
##l O
- O
1 O
of O
g O
##p O
##53 O
##1 O
using O
100 O
micro O
##lite O
##rs O
of O
plasma O
. O
[SEP] O
[CLS] O
our O
data O
show O
that O
m O
##od O
##ulation O
of O
m O
##4 O
and O
mg O
##lu O
##2 O
receptors O
may O
potentially O
be O
beneficial O
in O
the O
treatment O
of O
negative O
and O
cognitive O
symptoms O
of O
s O
##chi O
##zophrenia O
. O
[SEP] O
[CLS] O
one O
- O
hundred O
and O
fifty O
hi O
##rs O
##ute O
women O
( O
68 O
with O
type O
i O
or O
ii O
p O
##oly O
##cy O
##stic O
o O
##vary O
syndrome O
and O
82 O
with O
id O
##io O
##pathic O
hi O
##rs O
##uti O
##sm O
) O
were O
treated O
for O
periods O
of O
6 O
to O
48 O
months O
with O
oral O
c O
##y O
##p O
##rote O
##rone O
( O
c O
##pa O
) O
, O
a O
drug O
with O
peripheral O
anti O
##and O
##rogen O
##ic O
, O
anti O
##gon O
##ado O
##tro O
##phic O
and O
pro O
##ges O
##tative O
properties O
, O
and O
17 O
beta O
- O
est O
##rad O
##iol O
given O
per O
##cut O
##aneous O
##ly O
to O
ensure O
est O
##rogen O
##ic O
imp O
##re O
##gna O
##tion O
. O
[SEP] O
[CLS] O
a O
rapid O
onset O
of O
drug O
effect O
was O
observed O
for O
all O
c O
##lev O
##id O
##ip O
##ine O
co O
##hor O
##ts O
, O
with O
no O
evidence O
of O
a O
dim O
##ini O
##shing O
drug O
effect O
throughout O
the O
treatment O
period O
. O
[SEP] O
[CLS] O
specific O
features O
of O
drug O
distribution O
were O
detected O
; O
for O
example O
, O
s O
##ple O
##nic O
tissue O
selective O
##ly O
accumulated O
th O
##iet O
##az O
##ole O
during O
course O
treatment O
. O
[SEP] O
[CLS] O
blood O
samples O
were O
collected O
from O
all O
patients O
on O
day O
1 O
at O
the O
following O
times O
: O
0 O
( O
pre O
##dos O
##e O
) O
and O
15 O
min O
, O
30 O
min O
, O
1 O
h O
, O
1 O
h O
30 O
min O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
10 O
, O
and O
12 O
h O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
after O
50 O
##μ O
##l O
ta O
( O
k O
##ena O
##log O
- O
40 O
) O
su O
##pra O
##chor O
##oid O
##al O
injection O
, O
4 O
- O
5 O
animals O
at O
7 O
time O
points O
were O
sacrificed O
for O
a O
##que O
##ous O
, O
v O
##it O
##re O
##ous O
, O
re O
##tina O
, O
and O
plasma O
collections O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
of O
elimination O
estimated O
from O
the O
fourth O
twitch O
was O
similar O
to O
that O
from O
the O
first O
twitch O
. O
[SEP] O
[CLS] O
quality O
control O
( O
q O
##c O
) O
samples O
were O
obtained O
at O
5 O
, O
50 O
, O
160 O
ng O
/ O
m O
##l O
for O
ma O
##gno O
##f O
##lor O
##ine O
and O
α O
- O
all O
##oc O
##ry O
##pt O
##op O
##ine O
, O
at O
1 O
, O
10 O
, O
32 O
ng O
/ O
m O
##l O
for O
ski O
##mm O
##ian O
##ine O
. O
[SEP] O
[CLS] O
all O
the O
size O
of O
as O
##l O
- O
m O
##l O
formulation O
##s O
were O
around O
170 O
– O
200 O
nm O
with O
as O
##l O
- O
m O
##l O
( O
d O
##pp O
##g O
) O
smaller O
than O
as O
##l O
- O
m O
##l O
( O
h O
##sp O
##c O
) O
. O
[SEP] O
[CLS] O
steady O
state O
te O
##di O
##zo O
##lid O
had O
no O
effect O
on O
the O
p O
##k O
of O
pseudo O
##ep O
##hed O
##rine O
; O
the O
g O
##m O
##r O
and O
90 O
% O
c O
##is O
remained O
within O
the O
no O
- O
effect O
0 O
. O
8 O
to O
1 O
. O
25 O
boundaries O
( O
table O
1 O
) O
[ O
15 O
] O
. O
[SEP] O
[CLS] O
the O
accumulation O
of O
( O
+ O
) O
- O
and O
( O
- O
) O
- O
prop O
##rano O
##lo O
##l O
was O
investigated O
in O
nine O
subjects O
who O
received O
160 O
mg O
of O
race O
##mic O
prop O
##rano O
##lo O
##l O
as O
a O
single O
dose O
and O
then O
once O
daily O
for O
7 O
days O
. O
[SEP] O
[CLS] O
the O
mean O
cm B-PK
##ax I-PK
for O
male O
and O
female O
subjects O
was O
not O
statistical O
##ly O
significant O
but O
the O
extent O
of O
absorption O
appeared O
to O
be O
affected O
by O
sex O
. O
[SEP] O
[CLS] O
the O
en O
##cap O
##sul O
##ation O
efficiency O
( O
e O
##e O
, O
% O
) O
was O
expressed O
as O
the O
ratio O
of O
the O
p O
##t O
##x O
amount O
en O
##cap O
##sul O
##ated O
by O
the O
g O
##a O
mice O
##lles O
and O
the O
total O
p O
##t O
##x O
( O
100 O
% O
) O
amount O
in O
the O
mice O
##lle O
suspension O
, O
as O
described O
by O
equation O
( O
1 O
) O
: O
( O
1 O
) O
e O
##e O
% O
= O
( O
1 O
##− O
##w O
##f O
##w O
##to O
##tal O
) O
× O
##100 O
% O
where O
w O
##f O
was O
the O
weight O
of O
p O
##t O
##x O
in O
the O
fi O
##lt O
##rate O
, O
and O
w O
##to O
##tal O
was O
the O
weight O
of O
p O
##t O
##x O
in O
the O
formulation O
. O
[SEP] O
[CLS] O
electrical O
current O
in O
all O
cases O
was O
44 O
ma O
. O
[SEP] O
[CLS] O
volunteers O
receiving O
delayed O
- O
release O
me O
##sal O
##amine O
capsule O
##s O
with O
food O
were O
given O
a O
high O
- O
fat O
, O
high O
- O
ca O
##lor O
##ie O
( O
800 O
– O
1 O
, O
000 O
ca O
##lor O
##ies O
) O
breakfast O
30 O
minutes O
prior O
to O
dos O
##ing O
. O
[SEP] O
[CLS] O
introduction O
to O
p O
##har O
##ma O
##co O
##kin O
##etics O
: O
amino O
##gly O
##cos O
##ides O
in O
c O
##ys O
##tic O
fi O
##bro O
##sis O
as O
a O
prototype O
. O
[SEP] O
[CLS] O
a O
digital O
ca O
##lip O
##er O
was O
used O
to O
measure O
the O
tumor O
diameter O
##s O
( O
in O
mill O
##imeter O
##s O
) O
, O
and O
tumor O
volumes O
( O
in O
cubic O
mill O
##imeter O
##s O
) O
were O
calculated O
using O
the O
following O
formula O
: O
tumor O
volume O
= O
length O
##× O
##wi O
##dt O
##h O
##2 O
##× O
##0 O
. O
5 O
. O
[SEP] O
[CLS] O
effect O
of O
o O
##besity O
on O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
bio O
##log O
##ic O
effect O
of O
inter O
##fer O
##on O
- O
alpha O
in O
he O
##pa O
##titis O
c O
. O
[SEP] O
[CLS] O
in O
addition O
to O
receiving O
the O
study O
drug O
or O
place O
##bo O
, O
all O
participants O
receive O
i O
##v O
p O
##ca O
with O
h O
##ydro O
##mor O
##phone O
on O
demand O
to O
facilitate O
achieving O
adequate O
pain O
relief O
. O
[SEP] O
[CLS] O
as O
expected O
, O
there O
was O
a O
significant O
reduction O
in O
s O
##t O
##n O
##f O
- O
α O
in O
the O
as O
##cite O
##s O
fluid O
of O
in O
##f O
##lix O
##ima O
##b O
- O
treated O
mice O
when O
compared O
to O
vehicle O
( O
3 O
. O
7 O
- O
fold O
reduction O
, O
p O
< O
0 O
. O
000 O
##1 O
) O
. O
[SEP] O
[CLS] O
in O
addition O
, O
there O
was O
no O
wash O
##out O
period O
prior O
to O
the O
repeated O
administration O
phase O
( O
j O
##apa O
##n O
pharmaceutical O
information O
center O
registration O
no O
. O
j O
##ap O
##ic O
##ct O
##i O
‐ O
111 O
##48 O
##2 O
) O
. O
[SEP] O
[CLS] O
car O
##fi O
##l O
##zo O
##mi O
##b O
was O
administered O
on O
days O
1 O
, O
2 O
, O
8 O
, O
9 O
, O
15 O
and O
16 O
in O
28 O
- O
day O
cycles O
: O
15 O
mg O
/ O
m O
##2 O
( O
cycle O
1 O
) O
, O
20 O
mg O
/ O
m O
##2 O
( O
cycle O
2 O
) O
and O
27 O
mg O
/ O
m O
##2 O
( O
cycles O
3 O
+ O
) O
. O
[SEP] O
[CLS] O
the O
results O
show O
a O
highly O
significant O
increase O
in O
the O
ex O
##cre O
##tion O
of O
f O
##er O
##uli O
##c O
, O
is O
##of O
##er O
##uli O
##c O
, O
di O
##hy O
##dr O
##of O
##er O
##uli O
##c O
acid O
( O
3 O
- O
( O
4 O
- O
h O
##ydro O
##xy O
- O
3 O
- O
met O
##ho O
##xy O
##phe O
##ny O
##l O
) O
- O
prop O
##ion O
##ic O
acid O
) O
, O
and O
van O
##ill O
##ic O
acid O
posts O
##up O
##ple O
##mentation O
relative O
to O
the O
levels O
pre O
##su O
##pp O
##lement O
##ation O
. O
[SEP] O
[CLS] O
blank O
na O
##no O
##par O
##tic O
##les O
were O
produced O
in O
a O
similar O
manner O
without O
adding O
the O
drug O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
demonstrate O
that O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
α I-PK
in O
trans O
##der O
##mal O
application O
( O
13 O
, O
50 O
##6 O
. O
51 O
± O
164 O
##9 O
. O
92 O
ng O
· O
h O
/ O
m O
##l O
) O
was O
~ O
2 O
times O
higher O
( O
p O
< O
0 O
. O
000 O
##1 O
) O
as O
compared O
to O
oral O
dos O
##age O
form O
. O
[SEP] O
[CLS] O
by O
comparison O
p O
##b O
increased O
c O
##y O
##p O
##2 O
##b O
expression O
40 O
- O
fold O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##dynamic O
##s O
showed O
dose O
related O
beta O
2 O
responses O
for O
r O
- O
sa O
##l O
##but O
##amo O
##l O
and O
r O
##s O
- O
sa O
##l O
##but O
##amo O
##l O
but O
not O
for O
the O
s O
is O
##omer O
, O
and O
a O
plateau O
in O
response O
was O
not O
reached O
within O
the O
administered O
dose O
range O
. O
[SEP] O
[CLS] O
here O
, O
the O
design O
and O
optimization O
of O
novel O
[ O
1 O
, O
2 O
, O
4 O
] O
o O
##xa O
##dia O
##zo O
##le O
derivatives O
as O
selective O
s O
##1 O
##p O
receptor O
ago O
##nist O
##s O
are O
described O
. O
[SEP] O
[CLS] O
oral O
##ly O
administered O
a O
##ra O
- O
d O
##ma O
##p O
was O
rapidly O
absorbed O
. O
[SEP] O
[CLS] O
the O
more O
favorable O
results O
obtained O
with O
am O
##ox O
##ici O
##llin O
compared O
with O
those O
obtained O
with O
c O
##ef O
##uro O
##xi O
##me O
could O
be O
related O
to O
the O
anti O
##mic O
##ro O
##bial O
su O
##s O
##ce O
##pt O
##ibility O
of O
the O
p O
##ne O
##um O
##oc O
##oc O
##cal O
strain O
( O
mi O
##cs O
and O
minimum O
b O
##act O
##eric O
##idal O
concentrations O
of O
1 O
and O
1 O
micro O
##gram O
/ O
m O
##l O
and O
4 O
and O
4 O
micro O
##gram O
##s O
/ O
m O
##l O
for O
am O
##ox O
##ici O
##llin O
and O
c O
##ef O
##uro O
##xi O
##me O
, O
respectively O
) O
as O
well O
as O
to O
the O
better O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
obtained O
with O
am O
##ox O
##ici O
##llin O
. O
[SEP] O
[CLS] O
the O
c O
##y O
##c O
##lop O
##hos O
##pha O
##mi O
##de O
( O
si O
##gma O
chemical O
company O
in O
##c O
. O
, O
s O
##t O
lo O
##ui O
##s O
, O
m O
##o O
, O
u O
. O
s O
. O
a O
. O
) O
was O
administered O
in O
all O
animals O
from O
control O
( O
+ O
) O
, O
ex O
##p O
1 O
( O
+ O
) O
, O
and O
ex O
##p O
2 O
( O
+ O
) O
groups O
through O
a O
single O
in O
##tra O
##per O
##ito O
##nea O
##l O
injection O
only O
at O
29 O
d O
of O
experiment O
period O
. O
[SEP] O
[CLS] O
model O
selection O
was O
guided O
by O
evaluation O
of O
the O
minimum O
objective O
function O
and O
the O
weighted O
residual O
##s O
. O
[SEP] O
[CLS] O
in O
all O
cases O
, O
the O
drug O
almost O
totally O
disappeared O
from O
plasma O
within O
8 O
hours O
; O
drug O
levels O
measured O
prior O
to O
the O
first O
doses O
on O
the O
following O
days O
showed O
und O
##ete O
##ct O
##able O
levels O
. O
[SEP] O
[CLS] O
a O
maximum O
of O
six O
cycles O
were O
given O
. O
[SEP] O
[CLS] O
there O
was O
a O
good O
correlation O
between O
r O
##cc O
and O
p O
##cc O
( O
r O
= O
0 O
. O
7 O
) O
. O
[SEP] O
[CLS] O
the O
in O
##tra O
- O
ass O
##ay O
precision O
##s O
ranged O
from O
3 O
. O
8 O
to O
5 O
. O
9 O
% O
, O
while O
inter O
- O
ass O
##ay O
precision O
##s O
ranged O
from O
4 O
. O
2 O
to O
6 O
. O
0 O
% O
. O
[SEP] O
[CLS] O
both O
plasma O
( O
cm B-PK
##ax I-PK
: O
0 O
. O
54 O
- O
1 O
. O
10 O
- O
3 O
. O
12 O
µ O
##m O
) O
and O
u O
##rina O
##ry O
( O
cm B-PK
##ax I-PK
: O
0 O
. O
09 O
- O
0 O
. O
41 O
- O
0 O
. O
72 O
mg O
/ O
mg O
c O
##rea O
##tin O
##ine O
) O
an O
##ser O
##ine O
increased O
dose O
- O
dependent O
##ly O
following O
ing O
##est O
##ion O
of O
4 O
- O
10 O
- O
20 O
an O
##ser O
##ine O
mg O
/ O
kg O
b O
##w O
, O
respectively O
. O
[SEP] O
[CLS] O
for O
in O
##test O
##inal O
b O
##d O
patients O
, O
the O
clinical O
symptoms O
were O
scored O
at O
weeks O
0 O
, O
2 O
, O
and O
6 O
, O
and O
every O
4 O
weeks O
thereafter O
. O
[SEP] O
[CLS] O
the O
##o O
5 O
+ O
te O
##r O
20 O
, O
and O
the O
##o O
20 O
+ O
te O
##r O
20 O
enhanced O
the O
br O
##on O
##cho O
##di O
##lator O
action O
of O
each O
other O
in O
an O
add O
##itive O
manner O
. O
[SEP] O
[CLS] O
b O
##pa O
##f O
- O
g O
was O
further O
characterized O
by O
nuclear O
magnetic O
resonance O
( O
nm O
##r O
) O
. O
[SEP] O
[CLS] O
for O
both O
the O
p O
##ic O
and O
l O
##f O
##c O
, O
on O
day O
1 O
( O
co O
##hor O
##ts O
1 O
and O
3 O
) O
and O
day O
8 O
( O
co O
##hor O
##t O
1 O
only O
) O
, O
subjects O
received O
l O
##f O
##c O
( O
co O
##hor O
##t O
1 O
) O
or O
p O
##ic O
( O
co O
##hor O
##t O
3 O
) O
of O
p O
##ex O
##met O
##ini O
##b O
with O
240 O
m O
##l O
( O
± O
##10 O
m O
##l O
) O
water O
( O
ambient O
temperature O
) O
. O
[SEP] O
[CLS] O
[ O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
ca O
##uli O
##s O
er O
##y O
##ci O
##bes O
injection O
in O
rabbits O
] O
. O
[SEP] O
[CLS] O
summary O
statistics O
and O
statistical O
comparisons O
were O
, O
therefore O
, O
not O
performed O
for O
the O
10 O
‐ O
mg O
and O
20 O
‐ O
mg O
doses O
. O
[SEP] O
[CLS] O
z O
##op O
##ic O
##lone O
7 O
. O
5 O
mg O
has O
been O
compared O
also O
with O
te O
##ma O
##ze O
##pa O
##m O
20 O
mg O
in O
subjects O
with O
chronic O
ins O
##om O
##nia O
. O
[SEP] O
[CLS] O
rates O
of O
v O
##ld O
##l O
secret O
##ion O
were O
measured O
by O
determining O
the O
rate B-PK
of I-PK
accumulation I-PK
of O
t O
##rig O
##ly O
##cer O
##ide O
in O
the O
plasma O
after O
in O
##tra O
##ven O
##ous O
injection O
of O
anti O
- O
lip O
##op O
##rote O
##in O
lip O
##ase O
anti O
##body O
. O
[SEP] O
[CLS] O
the O
plasma B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
of I-PK
the I-PK
beta I-PK
- I-PK
phase I-PK
( I-PK
t I-PK
1 I-PK
/ I-PK
2 I-PK
beta I-PK
) I-PK
and O
time B-PK
to I-PK
maximum I-PK
peak I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
significantly O
longer O
in O
the O
elderly O
than O
in O
the O
young O
: O
t B-PK
1 I-PK
/ I-PK
2 I-PK
beta I-PK
, O
103 O
. O
8 O
+ O
- O
40 O
. O
6 O
versus O
59 O
. O
7 O
+ O
- O
16 O
. O
1 O
hours O
; O
and O
t B-PK
##max I-PK
, O
5 O
. O
2 O
+ O
- O
2 O
. O
8 O
versus O
3 O
. O
4 O
+ O
- O
1 O
. O
5 O
hours O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
objective O
of O
this O
study O
was O
to O
determine O
, O
in O
br O
##oil O
##ers O
, O
which O
m O
##oda O
##lity O
of O
di O
##so O
##dium O
f O
##os O
##fo O
##my O
##cin O
( O
d O
##f O
) O
administration O
and O
at O
what O
dose O
the O
best O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
profile O
could O
be O
obtained O
, O
taking O
as O
reference O
a O
110 O
field O
bacterial O
strains O
of O
es O
##cher O
##ichi O
##a O
co O
##li O
minimum O
inhibitor O
##y O
concentration O
survey O
. O
[SEP] O
[CLS] O
in O
cycle O
4 O
, O
the O
mean O
t O
##ras O
##tu O
##zu O
##ma O
##b O
exposure O
over O
the O
24 O
h O
following O
dose O
administration O
was O
3 O
, O
09 O
##4 O
μ O
##g O
* O
h O
/ O
m O
##l O
, O
which O
increased O
to O
a O
mean B-PK
concentration I-PK
of O
17 O
, O
322 O
μ O
##g O
* O
h O
/ O
m O
##l O
over O
the O
3 O
- O
week O
sampling O
interval O
. O
[SEP] O
[CLS] O
the O
steady B-PK
- I-PK
state I-PK
brain I-PK
- I-PK
to I-PK
- I-PK
free I-PK
plasma I-PK
concentration I-PK
ratio I-PK
of O
v O
##al O
##p O
##roi O
##c O
acid O
( O
v O
##pa O
) O
is O
well O
below O
unity O
, O
which O
suggests O
that O
it O
is O
efficiently O
removed O
from O
the O
central O
nervous O
system O
( O
c O
##ns O
) O
by O
specialized O
transport O
processes O
. O
[SEP] O
[CLS] O
after O
the O
subjects O
were O
pre O
##tre O
##ated O
with O
p O
##r O
##x O
for O
7 O
days O
or O
fl O
##v O
for O
6 O
days O
, O
a O
single O
dose O
of O
a O
##p O
##z O
was O
co O
##ad O
##mini O
##stered O
with O
p O
##r O
##x O
or O
fl O
##v O
under O
fast O
##ing O
conditions O
at O
the O
steady B-PK
- I-PK
state I-PK
plasma I-PK
concentration I-PK
of O
these O
s O
##s O
##ris O
, O
then O
repeated O
oral O
doses O
of O
s O
##s O
##ris O
were O
administered O
for O
14 O
consecutive O
days O
( O
period O
ii O
) O
( O
fi O
##g O
. O
1 O
) O
. O
[SEP] O
[CLS] O
internal O
##ized O
fraction B-PK
of I-PK
radio I-PK
##act I-PK
##ivity I-PK
was O
determined O
after O
l O
##ys O
##ing O
the O
cells O
with O
rip O
##a O
buffer O
. O
[SEP] O
[CLS] O
median O
plasma O
a O
##g O
##10 O
‐ O
a O
##g O
t B-PK
##max I-PK
was O
1 O
hour O
across O
all O
dose O
levels O
. O
[SEP] O
[CLS] O
these O
results O
suggest O
that O
combining O
the O
simplified O
in O
##test O
##inal O
availability O
model O
and O
in O
v O
##it O
##ro O
con O
##ju O
##gation O
ass O
##ay O
make O
it O
possible O
to O
predict O
human O
f B-PK
( I-PK
a I-PK
) I-PK
f B-PK
( I-PK
g I-PK
) I-PK
regardless O
of O
u O
##gt O
is O
##of O
##orm O
. O
[SEP] O
[CLS] O
the O
median O
plasma B-PK
equivalent I-PK
space I-PK
was O
found O
to O
be O
15 O
. O
9 O
l O
. O
/ O
m O
##2 O
, O
and O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
was O
40 O
. O
2 O
l O
. O
/ O
m O
##2 O
. O
[SEP] O
[CLS] O
the O
in O
v O
##ivo O
apparent B-PK
clearance I-PK
##s I-PK
of O
these O
compounds O
increase O
with O
dose O
. O
[SEP] O
[CLS] O
patient O
1 O
was O
given O
ran O
##iti O
##dine O
once O
or O
twice O
daily O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
we O
therefore O
performed O
a O
systematic O
study O
to O
identify O
the O
per O
##me O
##ation O
properties O
of O
g O
##eran O
##iol O
across O
in O
##test O
##inal O
cells O
, O
and O
its O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
after O
in O
##tra O
##ven O
##ous O
and O
oral O
administration O
to O
rats O
. O
[SEP] O
[CLS] O
there O
was O
no O
significant O
change O
in O
area B-PK
under I-PK
the I-PK
curve I-PK
or O
in O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
to O
##l O
##but O
##ami O
##de O
. O
[SEP] O
[CLS] O
the O
au B-PK
##cs I-PK
observed O
for O
the O
l O
##h O
- O
types O
were O
1 O
. O
8 O
times O
those O
of O
the O
h O
##l O
types O
. O
[SEP] O
[CLS] O
high O
i O
##ov O
on O
v B-PK
##1 I-PK
was O
observed O
, O
indicating O
important O
variation O
in O
v B-PK
##1 I-PK
from O
day O
to O
day O
within O
this O
population O
. O
[SEP] O
[CLS] O
patient O
demographic O
##s O
and O
characteristics O
are O
presented O
in O
table O
1 O
and O
supplement O
##ary O
table O
s O
##1 O
. O
[SEP] O
[CLS] O
previous O
models O
demonstrated O
that O
p O
##k O
parameters O
in O
neon O
##ates O
and O
infants O
were O
comparable O
to O
adolescent O
and O
adult O
populations O
after O
com O
##pen O
##sat O
##ing O
for O
both O
significantly O
decreased O
clearance B-PK
and O
longer O
terminal B-PK
elimination I-PK
half I-PK
‐ I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
serum I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
maximum B-PK
serum I-PK
concentration I-PK
( I-PK
c I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
) I-PK
, O
time B-PK
to I-PK
reach I-PK
the I-PK
c I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
( I-PK
t I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
) I-PK
, O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
( I-PK
& I-PK
f I-PK
##rac I-PK
##12 I-PK
; I-PK
) I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
( I-PK
d I-PK
) I-PK
) I-PK
and O
total B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
were O
calculated O
. O
[SEP] O
[CLS] O
clinical O
and O
##la O
##bor O
##atory O
base O
##line O
characteristics O
of O
these O
83 O
patients O
s O
##tra O
##ti O
##fied O
according O
to O
v O
##tl O
##are O
presented O
in O
table O
1 O
. O
[SEP] O
[CLS] O
the O
geometric O
mean O
vs B-PK
##s I-PK
( O
1 O
mg O
/ O
kg O
: O
80 O
. O
06 O
##2 O
m O
##l O
/ O
kg O
and O
10 O
mg O
/ O
kg O
: O
76 O
. O
217 O
m O
##l O
/ O
kg O
) O
is O
about O
twice O
the O
v B-PK
##1 I-PK
( O
1 O
mg O
/ O
kg O
: O
48 O
. O
85 O
##6 O
m O
##l O
/ O
kg O
and O
10 O
mg O
/ O
kg O
: O
44 O
. O
260 O
m O
##l O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##finity I-PK
values O
for O
unchanged O
c O
##p O
- O
93 O
, O
39 O
##3 O
were O
also O
greater O
for O
pm O
##s O
than O
for O
em O
##s O
, O
whereas O
the O
mean O
maximum B-PK
plasma I-PK
concentration I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##finity I-PK
values O
for O
total B-PK
radio I-PK
##act I-PK
##ivity I-PK
were O
similar O
for O
the O
two O
p O
##hen O
##otype O
##s O
. O
[SEP] O
[CLS] O
test O
conditions O
were O
the O
same O
as O
described O
in O
the O
“ O
flu O
##ores O
##cence O
properties O
of O
compound O
f O
” O
section O
. O
[SEP] O
[CLS] O
these O
showed O
that O
form O
##ono O
##net O
##in O
might O
still O
be O
a O
mainly O
active O
ingredient O
that O
we O
can O
detect O
in O
rat O
plasma O
. O
[SEP] O
[CLS] O
i O
##v O
clearance B-PK
and O
volume B-PK
of I-PK
distribution I-PK
were O
16 O
. O
8 O
l O
/ O
h O
and O
128 O
##5 O
l O
, O
respectively O
. O
[SEP] O
[CLS] O
dynamic O
( O
18 O
) O
f O
- O
fl O
##t O
pet O
imaging O
was O
performed O
for O
60 O
min O
in O
g O
##lio O
##ma O
- O
bearing O
mice O
( O
n O
= O
10 O
) O
and O
in O
non O
- O
tumor O
- O
bearing O
control O
mice O
( O
n O
= O
4 O
) O
by O
use O
of O
a O
dedicated O
small O
- O
animal O
pet O
scan O
##ner O
. O
[SEP] O
[CLS] O
a O
group O
of O
17 O
patients O
were O
enrolled O
in O
this O
trial O
. O
[SEP] O
[CLS] O
there O
is O
a O
wealth O
of O
evidence O
for O
the O
powerful O
anti O
##ox O
##ida O
##nt O
properties O
in O
v O
##it O
##ro O
of O
fl O
##av O
##ono O
##id O
components O
of O
the O
diet O
. O
[SEP] O
[CLS] O
a O
##rip O
##ip O
##raz O
##ole O
decreases O
b O
##p O
and O
increases O
h O
##r O
and O
q O
##t O
##c O
interval O
. O
[SEP] O
[CLS] O
overall O
, O
there O
appears O
to O
be O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
- O
p O
##har O
##ma O
##co O
##log O
##ic O
correlation O
between O
trim O
##op O
##ros O
##til O
plasma O
concentrations O
and O
in O
##hibition O
of O
gas O
##tric O
acid O
secret O
##ion O
. O
[SEP] O
[CLS] O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
was O
developed O
using O
non O
##me O
##m O
based O
on O
208 O
plasma O
and O
51 O
urine O
samples O
from O
20 O
i O
##cu O
patients O
during O
a O
median O
follow O
- O
up O
of O
3 O
days O
. O
[SEP] O
[CLS] O
al O
##iq O
##uo O
##ts O
of O
200 O
μ O
##l O
of O
6 O
% O
perch O
##lor O
##ic O
acid O
were O
added O
into O
the O
300 O
μ O
##l O
of O
blank O
or O
plasma O
sample O
in O
a O
1 O
. O
5 O
m O
##l O
micro O
##tub O
##e O
to O
pre O
##ci O
##pit O
##ate O
the O
protein O
. O
[SEP] O
[CLS] O
the O
initial O
pool O
sizes O
of O
1 O
##pec O
##d O
##f O
- O
derived O
radio B-PK
##act I-PK
##ivity I-PK
in O
the O
liver O
, O
muscle O
, O
skin O
, O
and O
ad O
##ip O
##ose O
tissue O
were O
43 O
, O
35 O
, O
10 O
, O
and O
7 O
% O
of O
the O
administered O
dose O
, O
respectively O
. O
[SEP] O
[CLS] O
it O
is O
established O
that O
r O
##u O
- O
120 O
##5 O
substance O
has O
high O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
44 O
. O
17 O
and O
56 O
. O
03 O
% O
upon O
per O
##oral O
and O
sub O
##cut O
##aneous O
introduction O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
however O
, O
one O
place O
##bo O
- O
treated O
individual O
had O
a O
“ O
pseudo O
- O
ex O
##ace O
##rb O
##ation O
” O
starting O
on O
study O
day O
13 O
characterized O
by O
uh O
##th O
##off O
’ O
s O
phenomenon O
lasting O
45 O
days O
, O
coincide O
##nt O
with O
onset O
of O
a O
u O
##rina O
##ry O
tract O
infection O
for O
two O
weeks O
and O
an O
overlapping O
period O
of O
blurred O
v O
##ison O
from O
study O
days O
29 O
– O
169 O
. O
[SEP] O
[CLS] O
for O
c O
##26 O
##h O
##22 O
##n O
##8 O
##o O
##6 O
##s O
##2 O
: O
c O
, O
51 O
. O
48 O
; O
h O
, O
3 O
. O
66 O
; O
n O
, O
18 O
. O
47 O
; O
s O
, O
10 O
. O
57 O
; O
found O
: O
c O
, O
51 O
. O
42 O
; O
h O
, O
3 O
. O
64 O
; O
n O
, O
18 O
. O
43 O
; O
s O
, O
10 O
. O
52 O
. O
[SEP] O
[CLS] O
this O
study O
establishes O
that O
a O
dose O
- O
es O
##cal O
##ation O
strategy O
for O
improving O
b O
##c O
##nu O
controlled O
- O
release O
polymer O
##s O
is O
more O
effective O
than O
adjusting O
the O
ratio O
of O
c O
##pp O
to O
sa O
to O
pro O
##long O
drug O
release O
. O
[SEP] O
[CLS] O
once O
a O
potential O
participant O
was O
identified O
, O
a O
parent O
was O
counsel O
##led O
in O
the O
presence O
of O
a O
senior O
staff O
nurse O
, O
and O
informed O
written O
consent O
was O
obtained O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
c O
##ef O
##uro O
##xi O
##me O
was O
studied O
in O
patients O
on O
continuous O
am O
##bula O
##tory O
or O
intermittent O
per O
##ito O
##nea O
##l O
dial O
##ys O
##is O
. O
[SEP] O
[CLS] O
a O
##v O
##s O
were O
scored O
by O
2 O
independent O
investigators O
who O
were O
blinded O
to O
treatment O
time O
points O
. O
[SEP] O
[CLS] O
ch O
##em O
##otherapy O
was O
delivered O
as O
outlined O
in O
table O
1 O
, O
case O
1 O
. O
[SEP] O
[CLS] O
for O
bio O
- O
distribution O
of O
g O
##d O
and O
g O
##d O
- O
t O
##s O
##ln O
##ps O
as O
shown O
in O
fi O
##g O
9 O
##a O
, O
the O
delivery O
of O
g O
##d O
through O
t O
##s O
##ln O
##p O
into O
liver O
, O
s O
##ple O
##en O
or O
lung O
was O
significantly O
high O
compared O
with O
g O
##d O
alone O
. O
[SEP] O
[CLS] O
to O
minimize O
the O
risk O
of O
treatment O
failures O
, O
toxic O
##ities O
, O
and O
other O
drug O
‐ O
related O
adverse O
events O
often O
associated O
with O
off O
‐ O
label O
p O
##ediatric O
dos O
##ing O
, O
regulatory O
agencies O
now O
require O
sponsors O
to O
submit O
p O
##ediatric O
trial O
plans O
at O
the O
end O
of O
the O
phase O
ii O
study O
( O
following O
the O
availability O
of O
exposure O
‐ O
response O
data O
in O
adults O
) O
and O
prior O
to O
the O
initiation O
of O
phase O
ii O
##i O
studies O
as O
part O
of O
new O
drug O
approval O
. O
[SEP] O
[CLS] O
in O
addition O
, O
in O
pro O
##ges O
##tero O
##ne O
- O
treated O
rats O
, O
levels O
of O
ben O
##zo O
##yle O
##c O
##gon O
##ine O
and O
e O
##c O
##gon O
##ine O
met O
##hyl O
##ester O
were O
higher O
at O
30 O
min O
post O
- O
administration O
than O
at O
15 O
min O
. O
[SEP] O
[CLS] O
ha O
##em O
##oly O
##ticus O
was O
less O
rapid O
and O
marked O
than O
against O
s O
##ta O
##ph O
. O
[SEP] O
[CLS] O
following O
oral O
administration O
of O
mon O
##tel O
##uka O
##st O
sodium O
, O
10 O
mg O
d O
- O
1 O
( O
the O
therapeutic O
regime O
##n O
for O
mon O
##tel O
##uka O
##st O
sodium O
) O
for O
7 O
d O
, O
there O
was O
little O
difference O
in O
the O
plasma O
concentration O
- O
time O
profiles O
of O
mon O
##tel O
##uka O
##st O
in O
young O
subjects O
between O
day O
1 O
and O
day O
7 O
dos O
##ing O
. O
[SEP] O
[CLS] O
the O
risk O
for O
other O
a O
##es O
did O
not O
significantly O
differ O
between O
treatment O
groups O
; O
however O
, O
de O
##ute O
##tra O
##ben O
##azi O
##ne O
was O
associated O
with O
numerical O
##ly O
lower O
risk O
of O
most O
of O
these O
a O
##es O
compared O
with O
te O
##tra O
##ben O
##azi O
##ne O
, O
except O
for O
coughing O
and O
di O
##ar O
##r O
##hea O
. O
[SEP] O
[CLS] O
although O
sub O
##cellular O
fraction O
##s O
were O
pro O
##cure O
##d O
for O
multiple O
organs O
, O
only O
the O
liver O
had O
all O
three O
fraction O
##s O
( O
c O
##yt O
##oso O
##lic O
, O
micro O
##so O
##mal O
, O
and O
s O
##9 O
) O
available O
. O
[SEP] O
[CLS] O
the O
clinical O
study O
was O
performed O
in O
accordance O
with O
the O
principles O
stated O
in O
the O
1964 O
he O
##ls O
##ink O
##i O
declaration O
and O
its O
subsequent O
amendments O
, O
good O
clinical O
practices O
( O
g O
##c O
##p O
; O
c O
##pm O
##p O
/ O
i O
##ch O
/ O
135 O
‐ O
95 O
) O
for O
trials O
on O
medicinal O
products O
and O
with O
h O
##uri O
##et O
law O
of O
20 O
de O
##ce O
##mber O
1988 O
, O
relating O
to O
the O
protection O
of O
individuals O
involved O
in O
bio O
##medical O
research O
in O
f O
##rance O
and O
its O
subsequent O
amendments O
. O
[SEP] O
[CLS] O
the O
p O
##eg O
##yla O
##ted O
lip O
##oso O
##me O
exhibited O
excellent O
co O
##llo O
##idal O
stability O
and O
was O
able O
to O
retain O
drugs O
en O
##cap O
##sul O
##ated O
, O
which O
were O
released O
in O
a O
slow O
and O
sustained O
fashion O
. O
[SEP] O
[CLS] O
a O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
was O
developed O
to O
investigate O
the O
effects O
of O
pregnancy O
on O
r O
##if O
##amp O
##in O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
in O
addition O
, O
these O
differential O
##ly O
abundant O
proteins O
were O
related O
to O
a O
variety O
of O
bio O
##film O
structures O
, O
suggesting O
that O
as O
extract O
could O
maintain O
the O
stability O
of O
mouse O
brain O
cells O
’ O
metabolism O
, O
control O
substances O
into O
and O
out O
of O
brain O
cells O
, O
and O
play O
essential O
roles O
in O
cell O
recognition O
, O
cell O
##ula O
##se O
synthesis O
, O
or O
other O
functions O
. O
[SEP] O
[CLS] O
in O
all O
cases O
car O
##bo O
##p O
##lat O
##in O
was O
administered O
di O
##lut O
##ed O
in O
5 O
% O
de O
##x O
##tro O
##se O
as O
a O
60 O
min O
in O
##tra O
##ven O
##ous O
in O
##fusion O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
##bet I-PK
##a I-PK
) I-PK
) I-PK
of O
f O
##x O
was O
longer O
in O
ducks O
than O
in O
br O
##oil O
##ers O
. O
[SEP] O
[CLS] O
[ O
pharmaceutical O
properties O
of O
r O
##ik O
##ku O
##ns O
##hit O
##o O
extract O
su O
##pp O
##os O
##itor O
##y O
and O
bio O
##e O
##qui O
##valence O
by O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
and O
effectiveness O
against O
nausea O
and O
vomit O
##ing O
and O
an O
##ore O
##xia O
in O
rats O
] O
. O
[SEP] O
[CLS] O
in O
addition O
, O
on O
imaging O
, O
non O
##tar O
##get O
em O
##bol O
##ization O
and O
other O
potential O
complications O
were O
recorded O
, O
including O
as O
##cite O
##s O
, O
p O
##le O
##ural O
fluid O
, O
gal O
##l O
##bla O
##dder O
wall O
thick O
##ening O
, O
and O
presence O
of O
bi O
##lo O
##mas O
or O
a O
##bs O
##cess O
##es O
. O
[SEP] O
[CLS] O
five O
to O
nine O
hundred O
- O
fold O
lower O
concentrations O
of O
t O
##ro O
##xa O
##ci O
##ta O
##bine O
were O
required O
to O
in O
##hibit O
cell O
growth O
in O
human O
compared O
with O
m O
##uri O
##ne O
tumor O
and O
normal O
hem O
##ap O
##oi O
##etic O
cell O
lines O
. O
[SEP] O
[CLS] O
z O
##ile O
##uto O
##n O
, O
a O
5 O
- O
lip O
##ox O
##y O
##gen O
##ase O
inhibitor O
, O
was O
evaluated O
as O
an O
inhibitor O
of O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
activity O
in O
human O
liver O
micro O
##some O
##s O
. O
[SEP] O
[CLS] O
for O
all O
study O
e O
##c O
##gs O
( O
periods O
1 O
- O
4 O
) O
, O
the O
over O
- O
reading O
card O
##iol O
##ogist O
##s O
were O
blinded O
to O
time O
, O
date O
, O
treatment O
and O
any O
data O
identifying O
the O
subject O
. O
[SEP] O
[CLS] O
half B-PK
- I-PK
life I-PK
was O
slightly O
, O
but O
statistical O
##ly O
significantly O
shorter O
in O
j O
##apa O
##nese O
than O
in O
ca O
##uca O
##sian O
subjects O
following O
single O
dose O
: O
ratios O
( O
95 O
% O
c O
##i O
) O
were O
0 O
. O
68 O
( O
0 O
. O
61 O
- O
0 O
. O
77 O
) O
for O
single O
dose O
, O
and O
1 O
. O
00 O
( O
0 O
. O
79 O
- O
1 O
. O
26 O
) O
for O
multiple O
dose O
. O
[SEP] O
[CLS] O
the O
aim O
of O
this O
study O
was O
to O
assess O
the O
population O
p O
##har O
##ma O
##co O
##kin O
##etics O
( O
p O
##k O
) O
of O
in O
##tra O
##ven O
##ous O
p O
##oly O
##my O
##xin O
b O
in O
patients O
with O
variable O
total O
body O
weights O
and O
create O
a O
population O
model O
for O
clinical O
use O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
do O
##xy O
##cy O
##cline O
pre O
- O
treatment O
increased O
the O
sensitivity O
of O
c O
##s O
##cs O
to O
radiation O
by O
up O
to O
4 O
. O
5 O
- O
fold O
. O
[SEP] O
[CLS] O
after O
this O
method O
was O
proven O
to O
be O
applicable O
in O
the O
detection O
of O
b O
##hm O
##c O
in O
rat O
plasma O
by O
giving O
accurate O
and O
precise O
results O
, O
it O
will O
be O
further O
applied O
in O
future O
research O
to O
determine O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
as O
well O
as O
the O
metabolism O
, O
distribution O
and O
ex O
##cre O
##tion O
of O
b O
##hm O
##c O
in O
rats O
to O
give O
a O
thorough O
overview O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
of O
b O
##hm O
##c O
since O
the O
major O
problems O
of O
cu O
##rc O
##umi O
##n O
are O
associated O
with O
its O
rapid O
clearance B-PK
from O
the O
body O
and O
low O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
plasma O
. O
[SEP] O
[CLS] O
this O
facilitate O
##s O
relatively O
straightforward O
##st O
##ructural O
characterization O
by O
nm O
##r O
s O
##pect O
##ros O
##copy O
. O
[SEP] O
[CLS] O
these O
data O
support O
the O
use O
of O
single O
- O
dose O
lip O
##eg O
##fi O
##l O
##gra O
##st O
##im O
6 O
mg O
in O
subsequent O
phase O
ii O
##i O
trials O
as O
prop O
##hyl O
##actic O
treatment O
for O
patients O
receiving O
my O
##elo O
##su O
##pp O
##ress O
##ive O
ch O
##em O
##otherapy O
. O
[SEP] O
[CLS] O
in O
subjects O
with O
moderate O
re O
##nal O
imp O
##air O
##ment O
, O
the O
g O
##me O
##an O
au B-PK
##c I-PK
##last I-PK
of O
94 O
##8 O
ng O
· O
h O
/ O
m O
##l O
was O
slightly O
increased O
compared O
with O
the O
value O
of O
77 O
##6 O
ng O
· O
h O
/ O
m O
##l O
in O
matched O
healthy O
controls O
; O
g O
##me O
##an O
cm B-PK
##ax I-PK
values O
were O
similar O
at O
28 O
. O
7 O
and O
28 O
. O
4 O
ng O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
op O
##ti O
##mized O
oral O
films O
were O
almost O
neutral O
to O
eliminate O
any O
possibility O
of O
irritation O
to O
the O
b O
##uc O
##cal O
m O
##uc O
##osa O
during O
administration O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
of O
a O
single O
oral O
dose O
of O
u O
##bs O
##10 O
##9 O
in O
mice O
revealed O
that O
peak B-PK
plasma I-PK
concentrations I-PK
were O
reached O
at O
0 O
. O
5 O
hours O
post O
- O
dose O
( O
t B-PK
##max I-PK
) O
with O
average B-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
131 O
and O
248 O
ng O
/ O
m O
##l O
for O
oral O
doses O
of O
50 O
and O
150 O
mg O
/ O
kg O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
profiles O
of O
me O
##lo O
##xi O
##cam O
following O
an O
oral O
administration O
of O
me O
##lo O
##xi O
##cam O
or O
its O
ethanol O
##amine O
salts O
were O
also O
evaluated O
in O
rats O
. O
[SEP] O
[CLS] O
treatment O
via O
this O
regime O
##n O
resulted O
in O
complete O
re O
##gression O
of O
the O
tumor O
in O
all O
animals O
by O
day O
22 O
; O
complete O
re O
##gression O
( O
c O
##r O
) O
occurred O
in O
4 O
of O
6 O
treated O
animals O
within O
31 O
days O
of O
post O
- O
treatment O
observation O
( O
fi O
##g O
. O
6 O
##a O
) O
. O
[SEP] O
[CLS] O
regardless O
of O
the O
optimal O
ratio O
selected O
, O
g O
##ati O
##f O
##lo O
##xa O
##cin O
had O
a O
higher O
probability O
of O
achieving O
the O
au B-PK
##c I-PK
: I-PK
mi I-PK
##c I-PK
target O
than O
did O
le O
##vo O
##f O
##lo O
##xa O
##cin O
. O
[SEP] O
[CLS] O
in O
this O
study O
, O
we O
directly O
incorporated O
a O
p O
##ediatric O
co O
##var O
##iate O
model O
for O
the O
g O
##lu O
##cu O
##ron O
##ida O
##tion O
of O
m O
##or O
##phine O
into O
a O
p O
##ediatric O
population O
model O
for O
z O
##ido O
##vu O
##dine O
g O
##lu O
##cu O
##ron O
##ida O
##tion O
. O
[SEP] O
[CLS] O
the O
n O
##s O
##5 O
##b O
s O
##28 O
##2 O
##t O
amino O
acid O
substitution O
, O
associated O
with O
al O
- O
335 O
in O
v O
##it O
##ro O
resistance O
, O
was O
not O
observed O
by O
sang O
##er O
population O
se O
##quencing O
in O
any O
of O
the O
subjects O
, O
either O
at O
base O
##line O
or O
emerging O
at O
the O
end O
of O
dos O
##ing O
or O
at O
the O
end O
of O
follow O
- O
up O
( O
day O
21 O
) O
. O
[SEP] O
[CLS] O
strict O
ad O
##herence O
to O
the O
university O
of O
lo O
##ui O
##sville O
institutional O
animal O
care O
and O
use O
committee O
( O
i O
##ac O
##uc O
111 O
##10 O
) O
approved O
protocol O
was O
maintained O
. O
[SEP] O
[CLS] O
the O
patches O
consisted O
of O
1 O
) O
the O
backing O
layer O
made O
of O
a O
water O
- O
ins O
##ol O
##ub O
##le O
polymer O
, O
2 O
) O
the O
drug O
- O
carrying O
layer O
composed O
of O
ca O
##ffe O
##ine O
and O
a O
gel O
- O
forming O
polymer O
, O
and O
3 O
) O
the O
enter O
##ic O
polymer O
membrane O
. O
[SEP] O
[CLS] O
the O
outcomes O
of O
this O
animal O
study O
are O
expected O
to O
serve O
as O
a O
basis O
for O
development O
of O
clinical O
guidelines O
on O
total O
p O
##eon O
##y O
g O
##lu O
##cos O
##ides O
usage O
. O
[SEP] O
[CLS] O
is O
##onia O
##zi O
##d O
, O
r O
##if O
##amp O
##in O
, O
et O
##ham O
##but O
##ol O
, O
and O
p O
##yra O
##zin O
##ami O
##de O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
treatment O
outcomes O
among O
a O
predominantly O
hi O
##v O
- O
infected O
co O
##hor O
##t O
of O
adults O
with O
tuberculosis O
from O
b O
##ots O
##wana O
. O
[SEP] O
[CLS] O
the O
other O
α O
‐ O
ad O
##rene O
##rg O
##ic O
receptor O
block O
##er O
that O
has O
been O
used O
during O
pregnancy O
is O
p O
##hen O
##ox O
##y O
##ben O
##zam O
##ine O
that O
binds O
i O
##rre O
##vers O
##ibly O
3 O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
p O
##har O
##ma O
##co O
##dynamic O
profiles O
of O
in O
##tra O
##ven O
##ous O
and O
oral O
do O
##xa O
##zo O
##sin O
were O
investigated O
in O
6 O
norm O
##ote O
##ns O
##ive O
volunteers O
. O
[SEP] O
[CLS] O
additional O
studies O
are O
required O
to O
further O
investigate O
c O
##y O
##p O
##45 O
##0 O
p O
##oly O
##mor O
##phism O
effects O
on O
et O
##ham O
##but O
##ol O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
group O
i O
received O
twice O
daily O
250 O
mg O
of O
metro O
##ni O
##da O
##zo O
##le O
( O
supplied O
as O
250 O
mg O
tablets O
v O
##agi O
##mi O
##d O
) O
. O
[SEP] O
[CLS] O
in O
a O
survey O
of O
290 O
patients O
with O
pm O
##d O
, O
muscle O
weakness O
, O
chronic O
fatigue O
, O
exercise O
into O
##ler O
##ance O
, O
gas O
##tro O
##int O
##est O
##inal O
problems O
, O
and O
balance O
problems O
were O
the O
5 O
most O
common O
symptoms O
experienced O
in O
> O
75 O
% O
of O
patients O
. O
7 O
primary O
mitochondrial O
my O
##op O
##athy O
( O
pm O
##m O
) O
is O
a O
pm O
##d O
affecting O
predominantly O
, O
but O
not O
exclusively O
, O
skeletal O
muscle O
. O
8 O
pm O
##m O
can O
be O
very O
di O
##sa O
##bling O
and O
adverse O
##ly O
affects O
patients O
' O
quality O
of O
life O
##9 O
, O
10 O
with O
no O
available O
treatments O
to O
be O
used O
aside O
from O
p O
##all O
##ia O
##tive O
approaches O
. O
1 O
, O
9 O
, O
11 O
[SEP] O
[CLS] O
the O
ass O
##ay O
ranges O
from O
25 O
to O
500 O
ng O
/ O
m O
##l O
with O
a O
functional O
sensitivity O
( O
at O
20 O
% O
coefficient O
of O
variation O
) O
of O
30 O
ng O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
we O
investigated O
the O
f O
##eas O
##ibility O
of O
using O
sa O
##liva O
for O
compliance O
monitoring O
of O
z O
##ido O
##vu O
##dine O
( O
z O
##d O
##v O
) O
, O
la O
##mi O
##vu O
##dine O
( O
3 O
##t O
##c O
) O
and O
ne O
##vir O
##ap O
##ine O
( O
n O
##v O
##p O
) O
in O
29 O
hi O
##v O
- O
1 O
infected O
patients O
from O
r O
##wan O
##da O
. O
[SEP] O
[CLS] O
the O
post O
##ulated O
role O
of O
p O
- O
g O
##p O
suggests O
that O
c O
##el O
is O
clinical O
##ly O
active O
, O
and O
advise O
##s O
caution O
in O
designing O
combinations O
of O
p O
##t O
##x O
with O
other O
drugs O
that O
are O
substrate O
for O
p O
- O
g O
##p O
. O
[SEP] O
[CLS] O
data O
were O
best O
described O
by O
a O
two O
- O
compartment O
model O
with O
first O
order O
absorption O
and O
parallel O
linear O
and O
non O
##linear O
elimination O
pathways O
. O
[SEP] O
[CLS] O
the O
ass O
##ay O
was O
linear O
up O
to O
400 O
ng O
/ O
m O
##l O
of O
s O
##n O
- O
38 O
in O
tissue O
ho O
##mo O
##gen O
##ates O
, O
and O
may O
be O
extended O
to O
120 O
micro O
##g O
/ O
m O
##l O
by O
proper O
di O
##lution O
of O
samples O
over O
the O
upper O
limit O
of O
q O
##uant O
##itation O
. O
[SEP] O
[CLS] O
in O
stage O
i O
##v O
patients O
, O
the O
onset O
of O
toxic O
##ities O
was O
also O
delayed O
with O
p O
##k O
monitoring O
( O
p O
= O
. O
06 O
##0 O
##5 O
) O
. O
[SEP] O
[CLS] O
actual O
p O
##har O
##ma O
##co O
##kin O
##etic O
sampling O
times O
were O
used O
in O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
; O
data O
points O
with O
missing O
dos O
##ing O
or O
sampling O
time O
information O
were O
excluded O
from O
the O
analysis O
. O
[SEP] O
[CLS] O
r O
- O
125 O
##5 O
##28 O
is O
a O
plasma O
meta O
##bol O
##ite O
and O
is O
cleared O
solely O
by O
c O
##y O
##p O
##2 O
##d O
##6 O
despite O
its O
acid O
##ity O
. O
[SEP] O
[CLS] O
est O
##imation O
of O
met O
##had O
##one O
clearance B-PK
: O
application O
in O
the O
management O
of O
cancer O
pain O
. O
[SEP] O
[CLS] O
h O
/ O
m O
##l O
, O
respectively O
, O
which O
were O
three O
##fold O
higher O
than O
those O
of O
s O
##yn O
- O
286 O
##9 O
. O
[SEP] O
[CLS] O
te O
##rb O
##ina O
##fine O
and O
dem O
##eth O
##yl O
##ter O
##bina O
##fine O
are O
only O
ex O
##cre O
##ted O
as O
trace O
amounts O
in O
urine O
. O
[SEP] O
[CLS] O
sample O
preparation O
involved O
only O
protein O
precipitation O
without O
any O
complicated O
extraction O
procedures O
decreasing O
analysis O
time O
. O
[SEP] O
[CLS] O
as O
for O
the O
c O
. O
- O
154 O
##7 O
##t O
> O
g O
variant O
, O
similar O
to O
the O
s O
##p O
##1 O
em O
##sa O
ass O
##ay O
, O
we O
confirmed O
the O
position O
of O
the O
d O
##na O
- O
us O
##f O
##1 O
complex O
in O
competition O
or O
super O
##shi O
##ft O
ass O
##ays O
after O
in O
##cu O
##bation O
of O
nuclear O
proteins O
with O
32 O
##p O
- O
labeled O
us O
##f O
##1 O
consensus O
o O
##li O
##gon O
##uc O
##leo O
##tide O
##s O
( O
lanes O
1 O
– O
3 O
, O
fi O
##g O
. O
2 O
##b O
) O
. O
[SEP] O
[CLS] O
the O
disposition O
characteristics O
of O
( O
- O
) O
- O
q O
##uin O
##uc O
##lid O
##in O
##yl O
ben O
##zy O
##late O
( O
q O
##n O
##b O
) O
were O
investigated O
in O
rats O
, O
and O
a O
physiological O
##ly O
based O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
was O
established O
using O
its O
linear O
and O
non O
##linear O
tissue O
binding O
parameters O
. O
[SEP] O
[CLS] O
β O
- O
car O
##ote O
##ne O
supplement O
##ation O
with O
50 O
, O
000 O
i O
##u O
per O
day O
for O
28 O
days O
also O
resulted O
in O
a O
significant O
increase O
in O
the O
c O
##d O
##4 O
+ O
% O
and O
c O
##d O
##4 O
+ O
: O
c O
##d O
##8 O
+ O
ratio O
in O
our O
subjects O
none O
of O
which O
had O
a O
base O
##line O
car O
##ote O
##ne O
deficiency O
. O
[SEP] O
[CLS] O
blood O
samples O
were O
collected O
in O
s O
##ter O
##ile O
p O
##oly O
##p O
##rop O
##yle O
##ne O
tubes O
for O
24 O
hours O
after O
each O
f O
##ent O
##any O
##l O
administration O
. O
[SEP] O
[CLS] O
the O
samples O
were O
son O
##ica O
##ted O
for O
5 O
minutes O
to O
dissolve O
the O
pre O
##ci O
##pit O
##ate O
, O
and O
the O
drug O
concentration O
in O
each O
sample O
was O
determined O
by O
hp O
##l O
##c O
ass O
##ay O
as O
mentioned O
above O
. O
[SEP] O
[CLS] O
the O
two O
o O
##me O
##pra O
##zo O
##le O
products O
failed O
to O
show O
bio O
##e O
##qui O
##valence O
, O
with O
the O
observed O
differences O
being O
even O
more O
apparent O
after O
multiple O
doses O
, O
as O
post O
##ulated O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
t I-PK
) I-PK
was O
increased O
by O
40 O
% O
( O
90 O
% O
c O
##i O
29 O
. O
1 O
, O
52 O
. O
0 O
) O
, O
but O
there O
was O
no O
effect O
on O
cm B-PK
##ax I-PK
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
p O
##t O
##x O
- O
l O
##pps O
with O
mass O
median O
a O
##ero O
##dynamic O
diameter O
( O
mm O
##ad O
) O
of O
5 O
. O
74 O
± O
0 O
. O
09 O
μ O
##m O
, O
high O
en O
##cap O
##sul O
##ation O
efficiency O
and O
good O
a O
##ero O
##sol O
##isation O
properties O
were O
produced O
using O
am O
##mon O
##ium O
bi O
##car O
##bon O
##ate O
as O
p O
##oro O
##gen O
. O
[SEP] O
[CLS] O
we O
recently O
proposed O
a O
p O
##oly O
- O
p O
##k O
strategy O
to O
character O
##ize O
the O
concentration O
- O
time O
profile O
and O
the O
metabolic O
response O
profile O
of O
multi O
##com O
##po O
##nent O
h O
##ms O
using O
an O
integrated O
p O
##hy O
##to O
##chemical O
and O
meta O
##bol O
##omi O
##cs O
approach O
. O
[SEP] O
[CLS] O
a O
prominent O
decrease O
in O
ps O
was O
observed O
, O
along O
with O
improved O
en O
##tra O
##pment O
efficiency O
, O
collectively O
( O
figure O
1 O
##c O
) O
. O
[SEP] O

